The Journal of the American Diabetes Association

diabetes

Volume 20 • 1971

INDEX

By Subject and Author

Copyright 1972, by American Diabetes Association, Inc.

DIABETES®

The Journal of the American Diabetes Association

EDITOR, HARVEY C. KNOWLES, JR., M.D., *Cincinnati*

ASSOCIATE EDITORS: DAVID M. KIPNIS, M.D., *St. Louis* • HENRY T. RICKETTS, M.D., *Chicago*

ADVISORY EDITORS: CHARLES H. BEST, M.D., *Toronto* • FRANK N. ALLAN, M.D., *Boston*

ABSTRACTS EDITOR, JOHN A. GALLOWAY, M.D., *Indianapolis* • MANAGING EDITOR, EDWARD W. SANDERSON, *New York*

EDITORIAL BOARD

TERM EXPIRING DECEMBER 1971

JAMES ASHMORE, PH.D., *Indianapolis*
RUBIN BRESSLER, M.D., *Tucson*
FREDERICK C. GOETZ, M.D., *Minneapolis*
CHRISTIAN R. KLIMT, M.D., DR. P.H., *Baltimore*
ARNOLD LAZAROW, M.D., PH.D., *Minneapolis*
RACHMIEL LEVINE, M.D., *Duarte, Calif.*
ALEXANDER MARBLE, M.D., *Boston*
THEODORE B. VAN ITALLIE, M.D., *New York*

TERM EXPIRING DECEMBER 1972

GEORGE F. CAHILL, JR., M.D., *Boston*
MARVIN CORNBLATH, M.D., *Baltimore*
T. S. DANOWSKI, M.D., *Pittsburgh*
PAUL E. LACY, M.D., *St. Louis*
HIROMICHI T. NARAHARA, M.D., *Albany*
DANIEL PORTE, JR., M.D., *Seattle*
GERALD A. WRENSHALL, PH.D., *Toronto*

TERM EXPIRING DECEMBER 1973

JOHN W. ENSINCK, M.D., *Seattle*
STEFAN S. FAJANS, M.D., *Ann Arbor*
GEROLD M. GRODSKY, PH.D., *San Francisco*
IRVING H. LEOPOLD, M.D., *New York*
ROGER H. UNGER, M.D., *Dallas*
PETER H. WRIGHT, M.D., *Indianapolis*

ABSTRACTORS

TERM EXPIRING DECEMBER 1971

BURIS R. BOSHELL, M.D., *Birmingham, Ala.*
PAUL S. ENTMACHER, M.D., *New York*
JEROME M. FELDMAN, M.D., *Durham*
RONALD K. KALKHOFF, M.D., *Milwaukee*
BERT F. KELTZ, M.D., *Oklahoma City*
THOMAS G. SKILLMAN, M.D., *Columbus, Ohio*
LEON S. SMELO, M.D., *Birmingham, Ala.*

TERM EXPIRING DECEMBER 1972

PAUL BECK, M.D., *Denver*
DAVID R. CHALLONER, M.D., *Indianapolis*
PHILIP FELIG, M.D., *New Haven*
J. D. GORMAN, M.D., *Indianapolis*
THOMAS J. MERIMEE, M.D., *Boston*
JAMES E. VANCE, M.D., *Indianapolis*

TERM EXPIRING DECEMBER 1973

GUENTHER BODEN, M.D., *Philadelphia*
HUEY G. MCDANIEL, M.D., *Birmingham*
SUMER PEK, M.D., *Ann Arbor*
PAUL S. ROSENFELD, M.D., *Milwaukee*
PAUL H. SCHREIBMAN, M.D., *New York*
CHARLES R. SHUMAN, M.D., *Philadelphia*

DIABETES is published by the American Diabetes Association, Inc., to provide an official Journal for the Association and to furnish the medical profession with information concerning diabetes and related fields of medicine.

Contributions are invited from practicing physicians, clinical and laboratory investigators, and others who have data of importance to offer in these fields. Manuscripts, if suitable, will be accepted providing that the text has not been printed elsewhere.

Matter appearing in DIABETES is copyrighted by the American Diabetes Association, Inc. Permission to reproduce all or parts of papers appearing in it may be granted under appropriate conditions and if proper credit is given. Such requests should be addressed in writing to the Secretary of the Association, accompanied by a letter of permission from the senior author.

All signed articles and editorials are the responsibility of the author(s) and not that of the American Diabetes Association. The Editors will be pleased to consider for publication papers presented at the Annual Meeting of the Association. *Manuscript Specifications*: The length of manuscripts (not including special articles or letters) should be limited to 5,000 words, exclusive of illustrations, etc. Exceptions to this limitation will be made at the discretion of the Editors.

Communications for the "Brief Notes and Comments" department should not exceed 1,000 words except in unusual circumstances. Figures and tables in these brief communications should be limited to one of each, and references should not exceed twenty in number.

Manuscripts should be typewritten, with double spacing and, if possible, submitted in triplicate together with three copies of figures and photomicrographs.

References should be presented in the style of the following examples: For Periodicals—Banting, F. G., and Best, C. H.: The internal secretion of the pancreas. J. Lab. Clin. Med. 7:251-66, Feb. 1922. For Books—Allen, Frederick M.: Studies Concerning Glycosuria and Diabetes. Cambridge, Harvard University Press, 1913, p. 461.

An abstract or summary of the content of the paper in not more than 250 words should usually appear at the beginning. This should be self-contained and understandable without reference to the text.

Photographs, drawings, and figures should be suitable for reproduction. Photographs should be unmounted, untrimmed glossy prints. The names of authors should appear on the back. The tops of photographs and figures should be indicated.

Galley proofs are sent to the principal author of each paper, with a price list and order blank for reprints.

All manuscripts and editorial correspondence should be addressed to the Editorial Office, DIABETES, American Diabetes Association, Inc., 18 East 48th Street, New York, New York 10017.

Subscription and Advertising Information

DIABETES: *The Journal of the American Diabetes Association* is published every month by the Association at 18 East 48th Street, New York, New York 10017.

© American Diabetes Association, Inc., 1972. All rights reserved under International and Pan-American Copyright Convention.

Members receive the Journal as part of their membership privileges. The annual subscription rates for nonmembers are as follows: United States, U. S. possessions, Canada and the Postal Union of the Americas and Spain, $20.00 for one year; $35.00 for two years; $50.00 for three years. Individual copies $2.00. For overseas subscriptions, add $2.00 per year for postage.

Medical students and physicians within five years after completion of medical school and bioscientists who are predoctoral or not more than two years postdoctoral: 50 per cent of the rates quoted in the previous paragraph, plus overseas postage where applicable.

Correspondence concerning subscriptions should be addressed to the Subscription Department, DIABETES. Checks, money orders and drafts for subscriptions should be made payable to the American Diabetes Association, Inc., and sent to the aforementioned address.

All inquiries about advertising and other business matters should be addressed to the Executive Director of the American Diabetes Association. The publishers reserve in their full discretion the right to accept or reject any proposed advertising and the right to cancel any advertising contract.

SUBJECT INDEX 1971

This index covers all reading matter in Volume 20 of DIABETES. Entries marked with an asterisk (*) indicate material that appeared in the Abstracts only. The Author Index appears on page 35.

A

AO44, *711
ACETATE
  and ethanol-induced gluconeogenesis suppression, *324
  metabolism
    by bovine cerebral cortex, *509
C-14-ACETATE
  uptake into aortic mucopolysaccharides and insulin, *312
ACETOHEXAMIDE
  and diabetic pregnancy
    and neonatal hypoglycemia, *314
  and insulin uptake by liver, *564
ACETONE
  and diabetic ketoacidosis, *252
ACETYLCHOLINE
  and insulin and glucagon release, 78-81
ACID-BASE HOMEOSTASIS
  and insulin, 793-794
  and renal glucose production, *124-125
ACIDOSIS, DIABETIC
  and glomerulosclerosis in children, 622
  and pneumomediastinum, *357
ACIDOSIS, LACTIC, *317-318
  in infants, *121
  and phenformin, *844
ACIDOSIS, METABOLIC
  and gluconeogenesis, 585
    and glutamine metabolism, *325
  and hyperlactatemia, *312
  and respiration, *364
ACID PHOSPHATASE
  in pancreatic beta cells of normal rats, 385-387
ACIDS
  acetoacetic
    and ketoacidosis, *252
  amino. *See* Amino acids
  alpha-amino-isobutyric
    fetal rat heart accumulation of, *351
  glutamic
    and kidney gluconeogenesis, *337
  linoleic
    metabolism in diabetic rat testicles, *123
  nicotinic
    and glucose tolerance, plasma insulin, and uric acid excretion, *355
    and plasma growth hormone, free fatty acids, and glucose, *562-563
  polyuridylic
    and protein synthesis by monosomes, 30
  quinolinic
    and P-enolpyruvate carboxykinase, *367
  sialic
    and insulin action on fat cells, *336
ACROMEGALY
  and blood-sugar response to prednisone, 413
  and growth hormone release, *358-359
  and thymus glands, *125
ACTH. *See* Adrenocorticotrophic hormones
ADDISON'S DISEASE
  and leucocyte migration test, 426
ADENOSINE 3', 5'-CYCLIC MONOPHOSPHATE
  and adipose tissue lipolysis, *349
    and antilipolytic compounds, 146-150
  and calcium uptake by beta cells, *328-329
  and glucagon, 129-133
  and gluconeogenesis and glycogenesis, *312
  glycogenolytic activity in perfused rat liver, *188
  and growth hormone, *313
  and insulin and glucagon secretion, 78
  and insulin secretion, *309, *374, 457-465
  and lipolytic action of growth hormone
    and glucocorticoids, *506-507
  and liver amino acid uptake, *183
  and RNA synthesis, *841
  and triiodothyronine, *183
ADENYLCYCLASE
  and glucagon binding in islet cells, *341
  and insulin and glucagon secretion, 78
ADIPOSE TISSUE
  blood flow
    and fat cell size and number, *709
  cell size, *563, *563-564
  and conversion of glucose to lipid, *315-316
  destruction, *563
  extracts
    and hypoglycemia, *707
  free fatty acid and ATP levels during lipolysis, *309
  glucose uptake
    and hepatoma, 610-611
  and glycogen synthetase, *844
  of hypothalamic obese rats, 660-661
  and insulin and proinsulin degradation, 276-281
  and insulin response during starvation, 46-50
  and insulin secretion study, 65-69
  insulin sensitivity
    in obese hyperglycemic mice, 522-534
    in rats adapted to periodic hyperphagia, *318
  lipogenesis
    in genetically obese rats, *310-311
    and growth hormone, *637
  lipolysis
    and cyclic AMP, *349
    and effect of antilipolytic compounds on cyclic 3',5'-adenosine monophosphate activation of, 146-150
  metabolism
    and diet, *348-349
    and theophylline and dibutyryl cyclic AMP, *380

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

and ventromedial hypothalamic lesions, *250, *357-358
and 3′, 5′-nucleotides metabolism, *310
in obese hyperglycemic mice, *184
and obesity, *336
and odd-carbon fatty acids, 200-204
rat
and insulin, 789
and mitochondria and pyruvate and lactate metabolism, *508
size, lipid, and enzymes
and nutrition, *506

ADOLESCENCE
and serum growth hormone response to hypoglycemia, *185

ADRENALECTOMY
and glucagon response, 131, 132
and ketosis, 96

ADRENAL GLANDS
lipids
and Wolman's Disease, *187
and progesterone and blood glucose levels, *254

ADRENERGIC BLOCKING AGENTS
See also Alpha adrenergic blocking agents; Beta adrenergic blocking agents
and basal insulin, *322
and glucose metabolism, *843
and insulin secretion, *309
and liver adenosine 3′, 5′-monophosphate, 131, 132
and renin secretion in dogs, *309

ADRENOCORTICAL GLANDS
and 1-24 corticotropin test, *844

ADRENOCORTICOTROPHIC HORMONES
and growth hormones and glucocorticoids, *776
insufficiency
and childhood hypoglycemia, *311

AFLATOXIN, *564

AGE
and absenteeism study of diabetics, *369-370
and angiopathy in mice, *314
and blood sugar levels, 405, 406, 811-814
and cholesterol levels, 103
and diabetes detection drive, 111
of diabetes onset
and vascular complications, *370
of diabetic
and knowledge of diabetes, 51
and diabetic ketoacidosis, 490-491
and diabetic ketoacidosis mortality, 492-493
and diabetic retinopathy, 816-823
gestational
and infant hypoglycemia, *778
and glucose tolerance, 102
and glucose tolerance and insulin secretion in mice, 134-138
and growth hormone response, *251-252
and insulin secretion study, 65-69
and leucocyte zinc in diabetics, 210
and pancreatic islets glucose metabolism, *710
of Pima Indians in diabetes survey, 756-765
and serum cortisol levels, *842
and serum immunoreactive insulin levels and prednisone, 411-413
and serum protein, *330
of subjects in plasma insulin response study, 398
and tolbutamide tests, *505

ALANINE
and kidney gluconeogenesis, *337

ALBUMIN
insulin antagonism to, *309

ALCOHOL
dehydrogenase, *187
and diabetic ketoacidosis, 494
ingestion
and lactic acidosis, *317
and insulin precipitation, 33-44

ALDOSTERONE
and pancreas insulin, *124

ALKALINE EARTH CATIONS
and insulin release, *445

ALLERGY
and 1-24 corticotropin tests, *844
to insulin, *563

ALLOXAN
action
and thiol compounds, *318

ALLOXAN DIABETES
and antibody responses, 162-166
and biotin and glucokinase, 632
and choline deficiency
and carnitine-C-14 metabolism, *445
compared with streptozotocin diabetes, *354
and gluconeogenesis and glycogenesis, *312
and hepatic enzymes, 71
and hypercholesterolemia, *713
and insulin
and heart glycerides and glycogen, *778
and kidney
and ribosomal protein synthesis, 649-654
and lactation and mammary tissue metabolism in rats, *636
and protein synthesis by liver ribosomes, 27-32
and renal glomerular basement membrane biosynthesis, 641-647
and S 1702 therapy, *353
and testicular atrophy in rats, *123

ALPHA-ADRENERGIC BLOCKING AGENTS
and immunoreactive insulin release, *776-777
and insulin and glucagon release, 78-81
and tolbutamide effects, *383

AMERICAN DIABETES ASSOCIATION
annual meetings
thirty-first, 61-62, 127, 190, 255, 319-320, 447, 510, 566-573
thirty-second, 510, 575, 719, 780, 846
awards
Gairdner Foundation, 784
Heath Memorial, 783
Lilly, 575, 639, 719, 780-781
research grants, 719
Committee on Affiliate Associations, 783
Committee on Camps, 782
Committee on Employment and Insurance, 782
Committee on Food and Nutrition, 781
Committee on Functions and Structure, 783
Committee on Future Annual Meetings, 781
Committee on Information for Diabetics, 782
Committee on Lay Awards, 782
Committee on Professional Education, 781
Committee on Professional Membership, 781
Committee on Public Education and Detection, 782
Committee on Regional Medical Programs and Diabetes Education Centers, 783
Committee on Research, 783
Committee on Scientific Affairs, 781
Committee on Scientific Programs, 781-782

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

Committee on Scientific Publications, 782
Committee on Statistics, 782
Committee on the Use of Therapeutic Agents, 782
committees and editorial boards for 1970-71, 62-64
DIABETES Editors, Editorial Board, and Abstractors, 782
Diabetes Mellitus: Diagnosis and Treatment, new volume available, 718
Diabetes Week, 447, 510, 575
Executive Committee, 781
FORECAST, 782
"Better Technics for Insulin Injection," 846
"Diabetes *Can* Travel with You!" 510
"Periodontal Disease and the Diabetic," 781
necrology, 64, 192, 320, 448, 576, 640, 720, 784
new members, 191-192, 255, 511, 846-847
News of Affiliate Associations, 128, 512, 639-640, 719-720
News Notes, 64, 128, 192, 256, 320, 448, 512, 575-576, 640, 720, 783, 847
Nominating Committee, 781
obituaries
Kimmelstiel, Paul, 117
personals, 64, 128, 192, 256, 320, 448, 512, 576, 720, 784
postgraduate courses, 62, 127-128, 190-191, 255, 320, 447, 510, 575, 576, 638, 714-718, 779-780, 783, 845-846
Research and Development Awards, 511, 574-575, 638-639, 718-719
Research Grants Program, 128
Special Committee, 783
submission of abstracts, 61-62
summer camp list, 255

AMES REFLECTANCE METER, *379

AMINO ACIDS
dietary disproportions of, *186
incorporation into protein
and diabetes, 28-29
-induced insulin release
and ethanol, *354-355
and insulin, 791-793
and insulin-glucagon ratio, 835-836
insulin response to
and 2-deoxy-d-glucose and mannoheptulose, *366
in premature infants, *358
metabolism
in fetal rat heart, *351
transport
and insulin, *842
uptake by liver
and glucagon, and cyclic 3′,5′-adenosine monophosphate, *183
uptake in muscle
and insulin, *60

AMMONIA
production
by renal cortex, *123

D-AMPHETAMINE
and hyperinsulinemia, *844

AMPUTATION
and diabetic ketoacidosis, 494-495
and infection, *347

AMYLO-1
and glycogen storage disease, *125

AMYOTROPHY, DIABETIC, *330

ANAPHYLAXIS
and alloxan diabetes, 162

ANEMIA
and chronic lactic acidosis of infancy, *121
and diabetes, *186

ANEPHRIC STATE
and insulin catabolism, 467-474

ANESTHETICS
local
and insulin secretion, 721-727

ANGIOGRAPHY
fluorescein
and diabetic retinopathy, 766-770
side effects, *311

ANGIOPATHY
and diabetes management, *125
and growth hormone, *188, 245
retinal
in diabetic mice, *314

ANOREXIA NERVOSA
and glucose, insulin and growth hormone relationships, *360-361

ANTIBODIES
binding
and glucagon, *446
to 2,4-dinitrophenylinsulin, *315
to gastrin
and cellular localization of gastrin, 389-391
to growth hormone, *777
to insulin, *505-506, *710
and insulin activity, *346
and insulin-resistant diabetes, *344
and proinsulin, *314, *446
in rats, *356-357
in normal and alloxan diabetic mice, 162-166
to thyroid, gastric and adrenal tissue and juvenile diabetes, *186

ANTIMYCIN A
and *Euglena gracilis* cultures, *777

ARGININE
and 2-deoxy-d-glucose, *366
and glucagon secretion, *710
and growth hormone secretion, *560
in obese children, *183
-induced growth hormone responses in children, *251-252
-induced insulin secretion, 449-455
and glucose, 171-176, *777
infusion
and glucose loading, *713
and pancreatic alpha-cell secretion, 838
and plasma insulin and blood glucose and ethanol pretreatment, *354-355

ARTERIOSCLEROSIS
and carbohydrate metabolism, *362

L-ASPARAGINASE
and carbohydrate metabolism, *253

ATHEROSCLEROSIS
and diabetes, *316
with hyperlipoproteinemia
and serum insulin, *122
and progeria, *564

ATP
and pancreas islet metabolism, 598-605

AUDITORY SYSTEM
and diabetes, *349

AUTOANALYZER
compared with Ames Reflectance Meter, *379
and comparison of diabetes screening methods, 109-116
and ferricyanide method, 129, 135

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

AUTOTRANSPLANTATION
of sheep pancreas
and insulin secretion studies, *560

AZOTEMIA
and bladder dysfunction, *313

B

BARORECEPTOR FUNCTION
and glucose administration, *182

BASEMENT MEMBRANE
capillary
and mild carbohydrate intolerance, *329
kidney
and glomerulosclerosis in children, 622-625
and glucosyltransferase and diabetes, 641-647
and microangiopathy, *126
ultrastructure studies, *443-444
muscle capillary
and carbohydrate intolerance, *329
thickening, *329
rat glomerular
and microangiopathy, *126

BELL'S PALSY
and diabetes, *563

BETA ADRENERGIC BLOCKING AGENTS
and glucose tolerance, *351-352
and insulin and glucagon release, 78-81
and insulin secretion, 721
and lipolytic effect of cyclic 3',5'-adenosine monophosphate, 146-150

BIGUANIDES, *509
and intestinal absorption
and glucose tolerance, *711
and pyruvate kinase, *325

BIOTIN
and alloxan diabetes, 632
deficiency
and glucokinase, 199, 213

BIRDS
glucagon infusion in, *121

BLADDER
asymptomatic neurogenic
and juvenile diabetes, *709
autonomic nerve fibers
and diabetes, *331-332
dysfunction
and diabetes, *313-314

BLOOD
acetoacetate and 3-hydroxybutyrate
and cortisol treatment, 94-95
in diabetes, 485-488
amino acids
circadian variation in neonate, *59
cholesterol and triglyceride
and sulfonylureas, *356
diurnal
and glucose and acetone bodies in juvenile diabetics, *182
flow
and adipose tissue cell size and number, *709
and glucagon, *560
and insulin and glucagon release study, 78
and insulin secretion, *843
and lipemia, *122
and serum protein changes, *330
hematocrit
in diabetic hyperosmolar syndrome study, 95
hypercoagulation
and glucose ingestion, *712
immunoreactive insulin
and tolbutamide, 686-690
insulin
and pancreatic insulin secretion, *60
leucocytes
glucose uptake studies, *709
zinc content, and diabetes, 206-212
lipids
and glucagon, *183
and hypercholesterolemia, *713
and low-sugar diet in hyperlipemia, *443
pH
and steroid treatment in rats, 94
red cells
and glucose transport, *335-336
rheology studies
and diabetes, *505
samples
in blood amino acids study, *59
in diabetic hyperosmolar syndrome study in rats, 93
and fasting and obesity study, 215
and glybenclamide study, 746-747
in metabolism and weight loss study, 85
of neonatal and adult mice, 135
in portal vein insulin study, 286-288
and sodium acetoacetate infusion study, *321
in study of maturity-onset diabetes, 45
sickle cell disease
and ketoacidosis, 771-773
thrombi
and hyperosmolar coma, 308
triglyceride, cholesterol, free fatty acids and glucose
in obese diabetics and nondiabetics, 216-217

BLOOD GLUCOSE. *See also* Blood sugar
and adipose tissue extracts, *707
and carbohydrate loading, *362-363
circadian
and weight change and sulfonylureas, *366
and coffee ingestion, *126
computer monitoring of, *362
and fasting, 797
and sulfonylureas, *356
and fluorescein retinal angiography, *311
and glucagon
in fetal rats, *444
and glucose tolerance tests in women, 429-433
and hyperosmolar coma, *253
and insulin, 786-790
and leucine and arginine
and ethanol pretreatment, *354-355
and mannoheptulose, *122, *508
and methylprednisolone, *327
and migraine, *778
in pig, *58
and prediabetic males, *371
in prediabetic women
and oral contraceptive agents, *507
and progesterone, *254
and prolonged fasting, *361
response to exercise and glucose infusion, *186-187
and sodium acetoacetate infusion, *321-322

BLOOD PRESSURE
and coronary artery disease, *506
intracranial
and hyperglycemia, *843
and ketoacidosis mortality, *347-348, 492
and retinopathy, *352-353

BLOOD SUGAR. *See also* Blood glucose
and age, 811-814
and age and weight, 405, 406
capillary

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

and cortisone-primed glucose tolerance tests in children, 615-621
and diabetes risk, *506
and diphenylhydantoin, 177-180
and glucagon infusion, *121
and hypothydroidism, *376
and jejunoileostomy, *124
and migraine, *778
and neurogenic bladder dysfunction, *313
regulation, *351-352
response to glucagon
and kidney failure, *252

BLOOD VESSELS. *See also* Capillaries; Vascular system
of eye
and pituitary ablation, *506
optic disc
and diabetic retinopathy, 816-823
retinal
and angiopathy, *314

BODY
fat
and insulin secretion, 65-69
feet
and osseous lesions, 302-307
forearm
and circulating insulin and proinsulin, *333-334
growth
and childhood hypoglycemia, *311
and plasma insulin, *560
growth retardation
and antibodies to growth hormone, *777
and hypopituitarism, *637
head injury
and carbohydrate metabolism, *364
height
and growth hormone, *560, *562
oral symptoms
and glucose intolerance, *373
temperature
and diabetic coma, *366-367
and immunoreactive insulin release, *776-777
and insulin secretion, *249
weight
and diabetes prevalence, 101-102
and diabetes risk, *506
and fenfluramine, *351
and urine insulin excretion, *123
weight and height
and serum immunoreactive insulin response to prednisone, 411-413

BONE
amino acid transport
and insulin, *842
lesions
and diabetes, 302-307

BOOK REVIEWS
Clinical Diabetes and Its Biochemical Basis, by W. G. Oakley, D. A. Pyke, and K. W. Taylor, 504
Controlling Diabetes with Diet, by Annette Gormican, 839
Diabetes Mellitus: Theory and Practice, edited by Max Ellenberg and Harold Rifkin, 504
Peripatetic Diabetic, The, by Margaret Bennett, 119
The Thyroid: A Fundamental and Clinical Text, 3rd edition, edited by S. C. Werner and S. H. Ingbar, 839

BOVRIL
and serum growth hormone, *562

BRAIN
degeneration
and chronic lactic acidosis of infancy, *121
disease
and blood glucose levels, *249
dog
glucose uptake by, *185-186
and galactosemia, *121
glucose assimilation studies, 519-521
glucose and lactate
and hypoxia, *254
and sickle cell disease, 773
temporal lobe epilepsy
and hypoglycemia, *375

BUCCAL MUCOSA
glycogen content, *445
and nutritional status, 167

BURNS
and insulin, 795-796

BUTYRATE
metabolism
by bovine cerebral cortex, *509

C

CAFFEINE
and glucose tolerance, *126

CALCIUM
and insulin secretion, *445, 721-727
migration
and phosphate, *841
uptake
and cyclic AMP, *328-329
by islets of Langerhans, 258, 263

CALORIES
control
and diabetes, 633-634
intake
and cholesterol levels, 104
and diabetes prevalence, 106

CAPILLARIES
basement membrane thickening
and mild carbohydrate intolerance, *329
blood flow
and lipemia, *122
blood sugar
and cortisone-primed glucose tolerance tests in children, 615-621
permeability
and S 1702 therapy, *353
skin
and long-term diabetes, 297-300
toe nailfold
and diabetes, *311

CARBOHYDRATES
dietary
and diabetes prevalence, 106
and lipid metabolism, 755
and fats
and hyperlipoproteinemia, *310
and glucose tolerance, *342-343
-induced hypertriglyceridemia
and phenformin, 739-743
intake
and diabetes, 633-634
and insulin, 786-790
intolerance
and lipemia, 214
and muscle capillary basement membrane thickening, *329
and liver glucose-6-phosphate dehydrogenase, 815, 823
loading
and blood glucose levels, *362-363
metabolism
and arteriosclerotic heart disease, *362
and L-asparaginase, *253
and baroreflex responses, *182
and head injury, *364
and heat acclimation, *708
and hyperosmolar nonketotic coma, *776

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

and liver insulin, *562
and 1-methyl-4-pyridinium chloride and phenformin, *840
and myocardial infarction, *564
in myocardium, *252
and palmitate metabolism, *840
and potassium depletion, *508
and respiratory gas exchange, *564
and scleroderma, *354
and weight loss, 83, 86-90
reserves
and infant hypoglycemia, *778
tolerance
and cirrhosis, and potassium, *372-373
and oral symptoms, *373
utilization
and vascular disease, *370

CARBON DIOXIDE
fructose-U-C-14 incorporation into, 195
glucose carbon incorporation into and starvation, 48-49
and mannoheptulose-C-14 metabolism by rat, 466
production
in heat-acclimated hamsters, *708

CARCINOMA
islet cell
and big insulin circulation, *334
and mannoheptulose, *122
liver
and glucagon therapy, *316

CARDIOVASCULAR DISEASE. *See also* Heart disease; Vascular disease
risk factors, *506

CARDIOVASCULAR SYSTEM. *See* Vascular system

CARNITINE-C-14
metabolism
and choline deficiency, *445

CARTILAGE
incorporation of leucine, *446

CASE REPORTS
Arthus and lupus erythematosus phenomenon and insulin therapy, *445
chronic lactic acidosis in infancy, *121
diabetes mellitus and Friedreich's ataxia, *123-124
diabetes and metyrapone, *313
diabetic glomerulosclerosis in children, 622
diabetic ketoacidosis, 490-499
diphenylhydantoin-induced hyperglycemia, 177-180
evolution of diabetes from hypoglycemia, *317
fatal venous thrombosis in hyperosmolar coma, 308
galactosemia, *636
growth-onset diabetes presenting with proliferative retinopathy, 626-627
hepatoma, hypoglycemia and insulin secretion, 607-608
hyperglycemic hyperosmolar nonketoacidotic coma
and diazoxide therapy in uremia, 501-503
hyperosmolar nonketotic coma, 229-230
and diazoxide therapy, *635
insulin allergy, 774-775
insulin-induced fat atrophy treatment, 628-631
insulin sensitivity and release following diabetic coma, 246-247
intravascular sickling and diabetic ketoacidosis, 771-773
juvenile diabetes
with pancreatitis, malabsorption, and IgA deficiency, *564
Launois-Bensaude adenolipomatosis, *508
osseous foot lesions and diabetic neuropathy, 302
postgastrectomy hypoglycemia, *58-59
progeria, *564
sporadic hypoglycemia, *636

CATABOLIC ILLNESS
and insulin-glucagon ratio, 834-837

CATARACTS
and chronic lactic acidosis of infancy, *121
and hyperosmolar nonketotic coma, *635

CATECHOLAMINES
and carbohydrate metabolism, 159
and fasting hypoglycemia
and pregnancy, *338
and gluconeogenesis and glycogenesis, *312
and insulin release, *561-562
precursors
and insulin secretion, *312-313
release
and propranolol, 721

CEBUS
and insulin immunoassays, *315

CEREBRAL CORTEX
metabolism studies, *509

CEREBRAL EDEMA
and diabetic glomerulosclerosis, 622

CEREBROVASCULAR ACCIDENTS
and diabetes, *316

CHARCOT JOINTS
and osseous lesions, 305

CHEROKEE INDIANS
diet and diabetes prevalence study, 103

CHICKENS
glucose metabolism and chronic acceleration, *312

CHILDREN
and chemical diabetes
and insulin response, 124
and 1-24 corticotropin test, *844
and cortisone-primed glucose tolerance tests
and capillary blood sugar, 615-619
and diencephalic syndrome
and growth hormone secretion, *189
and growth hormone secretion studies, *560
growth retardation
and hypopituitarism, *637
and hypoglycemia, *311, *507
and development of diabetes, *317
hypopituitary
and growth hormone, *124
and insulin response to glucose, *183
and malnutrition
and glucose tolerance and insulin secretion, *121-122
mentally retarded
and galactosuria screening tests, *250
multiphasic screening program, *374
obese
and growth hormone, *183
and insulin hypersecretion after L-leucine administration, *508-509
and insulin secretion cephalic phase, 800-802
and meal stimuli studies, *371
with protein-calorie malnutrition
and insulin secretion study, 542-550
and urine insulin, *123

CHIMPANZEE
and insulin immunoassays, *315

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

CHINESE HAMSTERS
and prediabetes, *356

CHLORPROMAZINE
and insulin release, *345-346

CHLORPROPAMIDE
and antidiuretic effect of vasopressin, *58
and diabetic pregnancy
and neonatal hypoglycemia, *314
-induced hypoglycemia, *356
and insulin and growth hormone, *365
and vasopressin, *60

CHOLESTEROL
and diabetes prevalence, 103-104
and diet, *709
metabolism, *59

CHOLESTEROLEMIA
and hypophysectomy and sympathectomy, 675

CHOLINE
deficiency
and carnitine-C-14 metabolism, *445
and insulin
and glycogen synthesis, *369

CHOLINERGIC DRUGS
and insulin release, 722-723

CHORIONIC GONADOTROPIN
and diabetic pregnancy, 696-704

CHORIONIC SOMATOMAMMOTROPIN
and progesterone-enhanced insulin production, *182

CHROMATOGRAPHY
gel
of diabetic mouse serum, 678
thin-layer
and proinsulin conversion to insulin, *332

CIRRHOSIS
and diabetes, *443, *708
and insulin, proinsulin and growth hormone release
and potassium, *372-373

CITRIC ACID CYCLE
and malate-aspartate shuttle
in rat heart mitochondria, *444

CLOFIBRATE
and serum lipids, 755

COFFEE
ingestion
and blood glucose and plasma insulin responses to glucose infusion, *126

COLCHICINE
and insulin release, 257, 259-260

COLLAGEN
synthesis
and glucose intolerance and hyperinsulinemia, *354

COMA
and glomerulosclerosis in children, 622
hyperosmolar
and venous thrombosis, 308
hyperosmolar nonketotic, 228-237, *253, 497, *843
and body temperature, *366-367
clinical observations, 231-232, 234-235
and diazoxide therapy, 501-503, *635
and improvement in insulin sensitivity, 246-248
and insulin-dependent diabetes, *561
and lipid carbohydrate metabolism, *776
treatment, 232-233, 236-237

COMPUTERS
and on-line blood glucose monitoring, *362

CONGENITAL ANOMALIES
and maternal glucose tolerance, *376

CONVULSIONS
and postgastrectomy hypoglycemia, *58-59

CORI CYCLE
and diabetes, *58

CORONARY DISEASE. *See* Cardiovascular disease; Heart disease

CORTICOSTEROIDS
and diabetic hyperosmolar syndrome, 92-97
and glucose tolerance, 414

CORTICOSTERONE
and diabetogenic effects study, *776
and glucose homeostasis, *713

1-24 CORTICOTROPIN TEST, *844

CORTISOL
assays, *844
and diabetic hyperosmolar syndrome, 94-97
diabetogenic effects study, *776
and metyrapone, *313

CORTISONE
and glucagon response, 131, 132
-induced hyperinsulinemia and growth hormone, *124
and ketosis, 96

CORTISONE GLUCOSE TOLERANCE TESTS, 615-621
and glucose-1-C-14 metabolism, *637
and muscle capillary basement membrane thickening, *329

COWS
hypocalcemic and parturient
and plasma calcium, glucose and immunoreactive insulin, *382-383
and insulin metabolism
and hypoglycemia, *710-711

P-CREATINE
and pancreas islet metabolism, 598-605

CUSHING'S SYNDROME
and thymus glands, *125

CYCLIC AMP. *See* Adenosine 3',5'-monophosphate

CYCLIC NUCLEOTIDES
and adipose tissue metabolism, *310

CYCLOHEXAMIDE
and adipose tissue lipogenesis, *637
and amino acid uptake by muscle, *60

CYSTIC FIBROSIS
and diabetes, *183
and glucose tolerance tests, *445

D

DEHYDRATION
and diabetic hyperosmolar syndrome, 92-97

2-DEOXY-D-GLUCOSE
and glucoregulatory hormone, *711
and mannoheptulose
and insulin response to amino acids, *366

DEOXYRIBONUCLEIC ACID. *See* DNA

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

DEUTERIUM OXIDE
and insulin release, 257-258, 260

DEXAMETHASONE
diabetogenic effects study, *776

DEXTROSTIX
and comparison of diabetes screening methods, 109-116

DIABETES INSIPIDUS
and chlorpropamide, *60

DIABETES KNOWLEDGE TESTS, 52-53

DIABETES MELLITUS
and abnormal insulin, 10-13
and absenteeism study, *369-370
and C-14-acetate and S-35-sulfate uptake into aortic mucopolysaccharides, *312
adult-onset
and insulin secretion and methysergide maleate, *321
and antipancreatic cellular hypersensitivity, 424-427
and arteriosclerosis
and carbohydrate metabolism, *362
and audiologic dysfunction, *349
and Bell's palsy, *563
and beta-cell activity
and serum C-peptide immunoreactivity, *332-333
and blood acetoacetate and 3-hydroxybutyrate, 485-488
"brittle"
and insulin-induced posthypoglycemic hyperglycemia, *310
and cerebrovascular accidents, *316
chemical
and insulin response, *124, 416-423
and cirrhosis, *443
complications
and lipoprotein patterns, *378
and cystic fibrosis, *183
detection
and prolonged fasting, *361
screening methods comparison study, 109-116
diagnosis
and Dupuytren's contracture, *125
and glucose tolerance tests, *374-375
and tolbutamide tests, *505
and diet, 633-634, *709
and pancreas beta-cell replication, *841
diuretic-induced
and hypertension, *842-843
and DNA synthesis, *253
duration
and nervous system changes, *251
and retinopathy, *352-353
and P-enolpyruvate inhibition by quinolinic acid, *367
evolution from hypoglycemia, *317
and fatty liver, *309
and fluorescein retinal angiography, *311
follow-up, *125
and Friedreich's ataxia, *123-124
and fructose infusion, 193
and L-fucose dehydrogenase, *369
and glucose ingestion
and plasma growth hormone levels, *363
and glucose uptake by blood leucocytes, *709
and glybenclamide, 745-754
and glycolysis and gluconeogenesis, *346
and glycoprotein synthesis, *376
and growth hormone secretion
and glucagon, *346-347
and heart and muscle peptide-chain initiation, *335
and hyperosmolar nonketotic coma, 228-237
and hypoglycemia
and renal insufficiency, *310
and infections, 162
and insulin administration via aerosol, 552-556
and insulin antagonism of albumin, *309
and insulin biosynthesis, 677-684
insulin-dependent
and hyperglycemic nonketotic coma, *561
and insulin-glucagon ratio, 834-837
insulin-resistant
and glucose metabolism, *58
and insulin antibodies, *344
and insulin secretion, 797-798
and secretin, *445
insulin-treated
and serum insulin levels, *368
and intraocular pressure, *635
juvenile, *841
and antibody studies, *186
and asymptomatic neurogenic bladder, *709
and blood and urine glucose and acetone bodies, *182
and diurnal serum growth hormone, 239-245
and glomerulosclerosis, 622-625
and growth hormone, *188
and growth hormone response to glucose load, *565
and fasting growth hormone levels, *565
and insulinemia, *188
knowledge of, 51-57
and neuromuscular abnormalities, *189
and pancreatitis, malabsorption, and IgA deficiency, *564
and partial remission, *361
presenting with retinopathy, 626-627
and pseudopapilledema, *711
and pulse wave velocity and tissue biopsy studies, *563
and reversible nervous abnormalities, *509
and serum calcium and magnesium levels after glucagon, *365-366
and sleep release of growth hormone, 691-694
and thymus glands, *125
and tolbutamide therapy, *358
and vascular changes, *313
and kidney
and ribosomal protein synthesis, 649-654
and Klinefelter's syndrome, *184-185
latent
and hypertriglyceridemia, *359-360
and lesions
and polyol pathway studies, *329
and leucocyte zinc, 206-212
-like syndrome
and encephalomyocarditis virus-injected mice, *561
and liver glycogen, *713
long-term
and absence of retinopathy, *375
and long-term survival, *316-317
management, 51-57, *125
maturity-onset
and glibenclamide therapy, *360
and glucose, free fatty acids, and insulin secretion, 45
and hyperosmolar nonketotic coma, *843
and insulin release, *349-350
and insulin responses to glucose and tolbutamide, *252-253
and insulitis, *341
and weight change and sulfonylurea treatment, *366

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

and metyrapone, *313
mild
and proinsulin secretion, *335
and muscle paralysis, *250-251
in *mystromys albicaudatus*, *123
and neurogenic vesical dysfunction, *313-314
and neutral regular insulin, *361-362
newly diagnosed
and re-establishment of normoglycemia, *323
and obesity
and fasting, 214-225
and pancreatic alpha-cell function, 838, 839
pathogenesis
and synalbumin insulin antagonist, *184
and Pima Indians, *348, 756-765
potential
and age and blood sugar values, 811-814
and portal vein insulin concentrations, 286-288
prevalence
and diet, 99-107
and protein synthesis, *373
and reactive hypoglycemia, 435, 437
and renal glomerular basement membrane glucosyltransferase, 641-647
and rheology of blood cells, *505
risk factors, *506
and RO 6-4563 therapy, *348
screening
and Ames Reflectance Meter and AutoAnalyzer technics, *379
and loading type and time of day, *370
sensitivity and specificity of tests compared, 289-295
and secretin, *322
and sensory perception thresholds, *330-331
and serum lipids and lipoproteins, *362
and serum protein changes
and blood flow, *330
and sexual dysfunction in females, 557-559
and skin capillary resistance, 297-300
and thymus glands, *125
and toe nailfold capillaries, *311
treatment, *509
and nerve conduction, *318
and tryptic inhibitor from salivary glands, *357
and Turner's syndrome and gonadal dysgenesis, *189
unstable
and growth hormone, *343-344
and urinary bladder nerve fibers study, *331-332
and urine 5-aminolevulinate and porphobilinogen, *708-709
and vascular disease
and carbohydrate utilization, *370
and nutrition, *350
and S 1702 therapy, *353

DIABETIC HYPEROSMOLAR SYNDROME
in rats, 92-97

DIARRHEA
in infants
and development of monosaccharide intolerance and hypoglycemia, *315

DIAZOXIDE
and hypoglycemia
and hyperosmolar nonketotic coma, *635
and infant hypoglycemia, *249
and insulin secretion, 449-455, 457-465
and islet cell tumors, *334-335
and pargyline-stimulated insulin secretion, 267
and uremia
and coma, 501-503

DIBUTYRYL CYCLIC AMP
and adipose tissue metabolism, *380

DICHLOROISOPROTERENOL
and adenylcyclase, 132
and liver adenosine 3',5'-monophosphate, 131

DIENCEPHALIC SYNDROME
and growth hormone secretion, *189

DIET. *See also* Nutrition
and amino acids, *186
and buccal smear technic, 167
carbohydrate and fat
and hyperlipoproteinemia, *249
carbohydrate-free
and infant hypoglycemia with diarrhea and monosaccharide intolerance, *315
and metabolism, *314
and serum glucose, insulin, and growth hormones, *343
and cortisone-primed glucose tolerance tests, 615
and diabetes, 633-634
and diabetes prevalence, 99-107
and diabetes treatment, *509
and electroretinograms in rats, *561
galactose-free
and pseudotumor cerebri in infants, *121
and galactosuria screening tests, *250
and gluconeogenesis and glycogenesis, *312
and hexosemonophosphate dehydrogenases
and RNA metabolism, 738, 744
high-carbohydrate
and improved glucose tolerance, *342-343
high-fat
and hypothalamic lesions, *505
high-protein
and gluconeogenesis, *353-354, 577-584
and plasma glucose, insulin, and insulin sensitivity, *310
and hyperglycemia, *709
and hyperlipemia, 833
and hyperlipoproteinemia, *250, *310
and hyperosmolar nonketotic coma, 229-230
and kidney metabolism, 396, 585, 728, 733
of larval blowflies
and taste responses, *841
and lipid metabolism, 755
low-carbohydrate
and metabolism, *253
low-leucine
and islet-cell tumor in newborn infant, *186
low-sugar
and hyperlipemia, *443
and meal ingestion in rats
and insulin, *254
and minerals, 139, 161
and obesity, *348-349
and odd-carbon fatty acids, 200-204
and pancreas beta-cell replication, *841
and pancreas insulin response to glucose, 586-590
and plasma insulin levels in sheep, *446
and plasma triglycerides
and hypothalamic lesions, 657-658
and postgastrectomy hypoglycemia, *58-59
of rats in pancreas beta-cell study, 16
and serum insulin in atherosclerotic patients with endogenous hypertriglyceridemia, *122

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

sucrose
and nephropathy in rats, 803-809
and vascular disease, *350
DIETHYLSTILBESTROL
and growth hormone secretion, *560
and obesity
and growth hormone, *315
DIHYDROERGOTAMINE
and cyclic AMP response to glucagon, 132
DIPHENYLHYDANTOIN
-induced hyperglycemia
and insulin release, 177-181
2, 3-DIPHOSPHOGLYCERATE
and insulin release, *328
DIURETICS
and diabetes
and hypertension, *842-843
DNA
synthesis
and diabetes and insulin, *253
DOG
brain glucose and lactate
and hypoxia, *254
and glucagon
and blood flow, *560
and glucagon secretion
and exercise, *339
and glucose turnover
and glucagon and insulin, *841
growth hormone and plasma glucose
and free fatty acids metabolism, *124
hyperglycemic
and intracranial pressure, *843
and plasma renin activity, *316
hypothalamus stimulation in, *841
and induced hyperinsulinemia, *711
and insulin secretion, *60
and obesity and infection, *382
in thoracic duct lymph, *251
and liver insulin extraction study, *341-342
pancreas
insulin inhibition study in, 1-9
pancreatectomized-sympathectomized
and somatotrophin action, 673-676
renal glucose production in, *124-125
renin response
and adrenergic blocking agents, *309
tetragastrin and glucagon secretion in, *122
DUCKS
glucagon infusion studies in, *121
and glucosamine stimulation of pancreatic glucagon secretion, *340
DULCITOL
and galactosemia in infants, *121
DUODENAL MUCOSA
and insulin secretion, *185
DUPUYTREN'S CONTRACTURE
and diabetes, *125
DWARFISM
and mental retardation
and growth hormone, *185

E

ELECTROCARDIOGRAMS
abnormality
and glucose tolerance, 105
in diabetes and diet study, 100, 104
and fluorescein retinal angiography, *311
ELECTROPHORESIS
lipoprotein
and hypertriglyceridemia, 658
ELECTRORETINOGRAMS
in sucrose- and starch-fed rats, *561
ENCEPHALOMYOCARDITIS VIRUS
and diabetes-like syndrome in mice, *561
ENCEPHALOPATHY
and fatty degeneration of viscera, *564
ENDOCRINE GLANDS
and glybenclamide, 745-754
and protein-calorie malnutrition, 549
P-ENOLPYRUVATE CARBOXY-KINASE
and quinolinic acid, *367
ENZYMES
of adipocytes
and nutrition, *506
and alloxan diabetes study, 632
and biguanide, *325
and genetic disease
and pyridoxine, *778
gluconeogenic
and diet, 396
and glycogen storage disease, *125
and glycolysis, 195-196
glycolytic and gluconeogenic
and diabetic rats, *346
in pre- and postnatal pigs, *712
hepatic
assay, 72
and streptozotocin diabetes, 71-77
insulin-specific protease, *342
kidney cortex
and diet, 728, 733
peroxidase
beta cell uptake of, *60
protease
with rat muscle insulin specificity, 140-144
and pyruvate carboxylase, *446
EPILEPSY
temporal lobe
and hypoglycemia, *375
EPINEPHRINE
and adrenergic control of basal insulin, *322
and glucose-stimulated insulin release, *188
and growth hormone, *313
and insulin blockade, *187
and insulin and glucagon release, 78-81
and insulin release, *445, *561-562
and pargyline-stimulated insulin secretion, 267
and reactive hypoglycemia, *374
and D-ribose
and plasma insulin, *562
renin response to
and adrenergic blocking agents, *309
secretion
and renin activity and hypoglycemia, *316
ERGOTAMINE TARTRATE
and progesterone, *254
ESTRADIOL
and glucose and insulin metabolism, 271-275
ESTRIOL
and glucose tolerance
and plasma insulin, 271-275
ESTROGEN
and diabetic pregnancy, 696-704
and growth hormone secretion, *560
ETHANOL
and gluconeogenesis
and acetate, *324
and hypoglycemia
and thyroxine, *254
and insulin release, 257-258

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

and leucine and arginine
and plasma insulin and blood glucose, *354-355
and phenformin
and hyperlacticacidemia, *324
and plasma insulin response to glucose and glucagon, 397-403

ETHYL ARACHIDONATE
and alloxan diabetic rats, *123

1-ETHYL-3-CARBODI-IMIDE
and insulin, *60, *316

ETHYL GLYCINATE
and insulin, *60, *316

N-ETHYL-3-TRIFLUOROMETHYL-PHENETHYLAMINE. *See* Fenfluramine

EUGLENA GRACILIS
and formation of giant mitochondria, *777

EXERCISE
and blood glucose and plasma insulin, *186-187
and glucagon secretion, *339
and growth hormone release during sleep, 694
and hypothalamus function, *840
and insulin release
and obesity, *183
and lactic acidosis, *317-318

EYE
intraocular pressure, *635
and long-term diabetes, *375
and pituitary ablation, *506
pseudopapilledema
and juvenile diabetes, *711

F

FAMILY HISTORY
and blood sugar response to prednisone, 414-415
and diabetes and Friedreich's ataxia in siblings, *123-124
and diabetes risk, *506
and glucose tolerance and serum insulin in identical twins, *509
and insulin response to glucose, *183
and plasma growth hormone response to glucose, *363
and sensory perception thresholds, *330-331

FASTING. *See also* Starvation
and adipose tissue metabolism, *380
and diabetes detection, *361
and glucose metabolism
and ganglionic blocking agents, *381
and hypoglycemia
and pregnancy, *338
and insulin, 796-797
and insulin reactions, *707
and migraine, *778
naturesis studies, *565

FAT
dietary
and diabetes, 633
and hyperlipoproteinemia, *310
intake
and diabetes prevalence, 106

FAT CELLS
enlarged, and insulin secretion, 67-69
sialic acid
and insulin response, *336

FATTY ACIDS
free
in adipocytes during lipolysis, *309
and central nervous system lesions, 158
and hyperosmolar nonketotic coma, *776
and hypophysectomy and sympathectomy, 674
and insulin secretion, 45,797
metabolism, *250, *314
in newborn infants, *713
and reactive hypoglycemia, *352
and hyperlipemia, 833
linoleic
and metabolism in diabetic rats testicles, *189
metabolism
and migraine, *778
odd-chain
and starvation, 200-204
and protein synthesis, *335
short-chain
and plasma insulin levels in sheep, *446
synthesis
and comparison of lipogenesis in mammalian tissues, *317
and insulin, *444
and protein, *708

FENFLURAMINE
and obesity
and plasma lipid and weight changes, *351

FETUS
endocrine pancreas
ultrastructure and insulin content, *381-382
growth
and insulin effectiveness, *363
growth hormone
and maternal glucose infusions, *254
management
and diabetic pregnancy, *355
mortality
and maternal ketoacidosis, 495-496
ovine
and insulin-induced hypoglycemia, *312
insulin secretion study, *776
pancreas
and insulin and glucagon release, *326-327
insulin release, 592-596
insulin response to glucose, 586-590
ultrastructure studies, *326
pancreatic epithelium, *326
pancreatic islets
and insulin release, *185
prognosis
and serum heat-stable alkaline phosphatase, *367
rat heart
alpha-amino-isobutyric acid accumulation, *351
and intrauterine injection of glucagon, *444
plasma and pancreas insulin studies in, *360
and streptozotocin diabetes, *562
and urine estriol, *311

FREEZE-ETCH TECHNIC
and pancreas ultrastructure studies, *326

FRIEDREICH'S ATAXIA
and diabetes, *123-124

FRUCTOSE
and gluconeogenesis
and glucagon, *324-325
glucose production from, 193-198
ingestion
and myocardial infarction, *564
metabolism
and age and strain in rats, 518, 551
in rat liver, *637

FRUCTOSE, 1,6 DIPHOSPHATASE, 196
and mannoheptulose, *188

FRUCTOSE-1-PHOSPHATE, 197

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

FRUCTOSE-U-C-14
and gluconeogenesis and glycogenesis and diet and hormones, *312
incorporation into carbon dioxide, 195
incorporation into glucose, 194-195

L-FUCOSE DEHYDROGENASE
and diabetes, *369

G

GALACTOSE
absorption from small intestine and hypophysectomy, *562
and insulin secretion, *317

GALACTOSE-1-PHOSPHATE
uridyl transferase, *635-636

GALACTOSEMIA
Indiana variant, *636
and pseudotumor cerebri in infants, *121
and unstable galactose-1-phosphate uridyl transferase, *635-636

GALACTOSURIA
screening tests, *250

GANGLIONIC BLOCKING AGENTS
and glucose metabolism, *381

GANGRENE
and osseous foot lesions, 305

GASTRECTOMY
and hypoglycemia, *58

GASTRIN
cellular localization in human pancreas, 389-395

GASTROINTESTINAL SYSTEM
absorption
and biguanides, *711
and alimentary hypoglycemia, *344
and cholesterol metabolism, *59
duodenal mucosa
and insulin secretion, *185
glucose and galactose metabolism and hypophysectomy, *562
and jejunoileostomy, *124
jejunum
and diabetes, *346
malabsorption
and juvenile diabetes, *564

GENES
and diabetes in Chinese hamsters, *356
and diabetes complications
and lipoprotein patterns, *378
and diabetes with Friedreich's ataxia, *124
and growth hormone sleep release, 694
and Klinefelter's syndrome and diabetes, *184-185

GENETIC DISEASE
pyridoxine-responsive, *778

GLIBENCLAMIDE, *509
and diabetes treatment, *348
and maturity-onset diabetes
and insulin response to glucose, *360

GLUCAGON
binding to plasma membranes, *340-341
bioassay, *317
biosynthesis, *338-339
and blood flow studies in dogs, *560
and evolution of diabetes from hypoglycemia, *317
in fetal rats
and blood glucose and liver carbohydrate, *444
and gluconeogenesis, *324-325
and gluconeogenesis and glycogenesis, *312
and glucose turnover, *841
and growth hormone secretion
and diabetes, *346-347
immunogenicity study, *446
infusion
and plasma free fatty acids and triglycerides, blood sugar and liver lipids, *121
-insulin ratio
and catabolic diseases, 834-837
and insulin secretion, 457-465
from human fetal pancreatic islets, *185
liver adenosine 3',5'-monophosphate response to, 129-133
and liver amino acid uptake, *183
and pancreas alpha-cell structure, *708
plasma insulin response to
and ethanol, 397-403
and protein
and insulin, 790-791
radioimmunoassay, *188
release
and autonomic nervous system, 78-81
from fetal pancreas, *326-327
and secretin, *339, 838, 839
secretion
and alpha-cell function, 288, 296
and arginine and histidine, *710
and oxytocin, *187
and tetragastrin, *122
and serum calcium and magnesium in juvenile diabetics, *365-366
serum growth hormone response to, *565
therapy
and hypoglycemia and liver carcinoma, *316
and thyroid function, *311
tolerance tests
and weight loss in obese subjects, 86-87
and transfer of plasma lipid to platelets, *183

I-125-GLUCAGON
binding in islet cells, *341

GLUCOCORTICOIDS
diabetogenic effects of, *776
and glycogen synthesis, *369
and growth hormone
and protein synthesis, *506-507
and hexose uptake by mouse fibroblasts, *507
and ketosis, 96
and liver adenosine 3', 5'-monophosphate, 132
and pancreas beta-cell replication, *327

GLUCOKINASE
and alloxan diabetes, 632
in diabetic rat, 199, 213
and glycolysis, 196

GLUCONEOGENESIS, *125
and biguanides, *325
and cyclic AMP, *123
and diet and hormones, *312
and enzymes, 196-197
and diabetes, *346
and fructose
and glucagon, *324-325
and ketogenesis, *323-324
kidney and liver, 585
and pyruvate recycling, *507
and quinolinic acid, *367
and triglyceride synthesis, 224-225

GLUCOSAMINE
and glucagon secretion, *340

GLUCOSE. *See also* Glucose intolerance; Glucose tolerance
absorption from small intestine and hypophysectomy, *562
administration
and baroreceptor function, *182
and arginine-induced insulin secretion, 171-176, *777

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

availability
in starved and acclimated mice, *709
and beta-cell insulin study, *443
conversion to fatty acid, *444
conversion to lipid
by adipose tissue, *315-316
disposal rate, *565
and pregnancy, *350-351
galactose conversion to, *317
and growth hormone release in sleep, *565
homeostasis
and corticosterone treatment in infancy, *713
-induced insulin release
and epinephrine and alkaline earth cations, *445
and streptozotocin, 513-517
infusion
blood glucose and plasma insulin response to, *186-187
and fetal growth hormone levels, *254
and insulin response in children, *183
and insulin secretion, *323
plasma insulin response to, and coffee ingestion, *126
ingestion
and hypercoagulation, *712
and plasma growth hormone, *363
and insulin, 786-790
and insulin release and chlorpromazine, *345-348
and 2,3-diphosphoglycerate, *328
from fetal rat pancreas, 592-596
and islets of Langerhans, 257-264
and prostaglandins, *374
and sulfhydryl-binding reagents, *382
insulin response to
and glibenclamide therapy, *360
and maturity-onset diabetes, *252-253
in premature infants, *358
in rat pancreas islets, *327
and insulin secretion, 4, 45, 449-455, 457-465
in autotransplanted pancreas, *560
and pargyline, 267-268
loading
and arginine infusion, *137
in chemical diabetics, *124
growth hormone response to, *565
and metabolism, *711
and PIDH, 734-737
and plasma insulin response in normal subjects, 729-732
metabolism
and adrenergic blockade, *843
by bovine cerebral cortex, *509
and chronic acceleration, *312
and chronic tolbutamide treatment, *337
and diabetic pregnancy, 696-697
and ganglionic blocking agents, *381
and glucoregulatory hormone, *711
kinetics of, *58
in normal and hypoglycemic cows, *710-711
and obesity, *58
and pancreatic islets of fetal, newborn, and adult rats, *710
in perfused rat pancreas, *327-328
and potassium chloride, *443
in rat liver, *637
and starvation, 46-50
and uremia, *562
oxidation
and ventromedial hypothalamic lesions in rats, *250
and pancreatic alpha cell secretion, 838-839
plasma insulin response to
and ethanol, 397-403
and portal and peripheral vein immunoreactive insulin, 168-170
production
from fructose, 193-198
and insulin-glucagon ratio, 834-835
and ketogenesis and gluconeogenesis, *323-324
by renal cortex, *123
and tumors, *122
production and utilization studies, *636
response
in Macaque monkeys, 156-160
and prediabetes, *364
transport
and red cells, *335-336
turnover
and glucagon and insulin, *841
and insulin antagonism in obesity, *336
uptake
by isolated dog brain, *185-186
uptake by leucocytes
and diabetes, *709
utilization
and carbohydrate-free diet, *314
in diabetic rats, *346

GLUCOSE-C-14
formation, *323-324

GLUCOSE I-C-14
assimilation studies, 519-521
C-14-O_2 production from
and insulin, *383
metabolism
during cortisone glucose tolerance tests, *637

GLUCOSE INTOLERANCE
and head injury, *364
and hyperinsulinemia
and scleroderma, *354
and hypobaric-hyperoxic environment, 282-285
in offspring of single-dose alloxanized rats, *637
and oral symptoms, *373
and uremia, *565

GLUCOSE OXIDASE MICROMETHOD, 135

GLUCOSE-6-PHOSPHATASE, 196
and glycogen storage disease, *125
in hyperthyroid mice, *254
in streptozotocin-diabetic rats, 71-77

GLUCOSE-6-PHOSPHATE DEHYDROGENASE
and dietary carbohydrate and insulin, 815, 823

GLUCOSE TOLERANCE
and age, 65
and anorexia nervosa, *360-361
and L-asparaginase, *253
and beta adrenergic blockade, *351-352
and biguanides, *711
and caffeine, *126
and cholesterol level, 103-104
and diabetes with Turner's syndrome, *189
diurnal variation of, *707
and glybenclamide, 749
and high-carbohydrate diet, *342-343
and hypertension
and diuretic therapy, *842-843
and hypophysectomy, *712
and identical twins of diabetics, *509
and kwashiorkor, 542
and malnourished children, *121-122
mildly abnormal, *707
in neonatal and adult mice, 134-138
and nicotinic acid, *355
in obese hyperglycemic mice, *184
and oral contraceptives, *187
postpartum
and maternal prediabetes, *375-376

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

and progesterone and chorionic somatomammotropin
and estriol, 271-275
and RO 6-4563, *348
and secretin, *322
and urine polypeptide of lipoatrophic diabetics, *315

GLUCOSE TOLERANCE TESTS
and chemical diabetes, 417-423
and cirrhosis, *708
in comparison of diabetes screening methods, 109-116
consecutive
and disposal factors, *565
cortisone-primed
and capillary blood sugar, 615-621
and cystic fibrosis, *445
and diabetes diagnosis
and one-hour and two-hour glucose levels, *374-375
and diabetes screening of children, *374
and diphenylhydantoin, 177-181
and Dupuytren's contracture, *125
and exercise, *183
in fasting obese diabetics and nondiabetics, 218-221
and glucose loading in normal subjects, 729-732
and hypoglycemia
and proinsulin levels, *353
and hypothyroidism, *376
and impotence, 559
and insulin secretion study, 66-69
intravenous, *635
in pig, 58*
and jejunoileostomy, *124
and metyrapone, *313
in monkeys, 151-152
and muscle capillary basement membrane thickening, *329
in neonatal and adult mice, 135, 137
normal
and positive prednisolone glucose tolerance test in pregnancy, *367-368
and normal and diabetic pregnancy, *380-381
and oral symptoms, *373
in overweight newborn infants and their mothers, *123
among Pima Indians
, and bimodality of distributions, 756-765
and pregnancy
and fetal outcome, *508
and reactive hypoglycemia, *352
serum immunoreactive insulin levels during, 404-408
and prednisone, 410-415
and sex differences, *378-379
and time of day administered, *314
in women, 428-433

GLUCOSE-U-C-14-CARBON
incorporation into carbon dioxide and starvation, 48-49

D-GLUCOSE
assimilation into retina, brain and other tissues, 519-521

6-GLUCOSIDASE
and glycogen storage disease, *125

GLUCOSURIA
and insulin dosage, *182

GLUCOSYLTRANSFERASE
and diabetes, 641-647

GLUTAMATE
glucose production
and cyclic GMP, *123

GLUTAMINE
glucose production
and cyclic GMP, *123
and kidney gluconeogenesis, *337
metabolism
and acidosis, *325

GLUTATHIONE-INSULIN TRANSHYDROGENASE
and insulin metabolism, *342

GLYBENCLAMIDE
mechanism of action, 745-754

GLYCEROL
metabolism
in neonatal rat, *126

GLYCEROL-2-C-14
and gluconeogenesis and glycogenesis and diet and hormones, *312

GLYCEROL-3-PHOSPHATE
and lipid synthesis, *310-311

GLYCOGEN
in clinical leukoplakia, *445
metabolism
by lean and obese mouse pancreas, *379-380
nephrosis, 622
stores
and plasma insulin, *560
synthesis
and glucocorticoids, *369
turnover, *713

GLYCOGENESIS
and diet and hormones, *312

GLYCOGEN STORAGE DISEASE, *125

GLYCOGEN SYNTHETASE
in rat adipose tissue, *844

GLYCOLYSIS, *125
and enzymes, 195-196
and diabetes, *346

GLYCOPROTEIN
synthesis
and diabetes, *376

GLYCOSURIA
in comparison of diabetes screening methods, 112-115
management, *125
and pregnancy, 476-483

GOLD THIOGLUCOSE
and hypothalamic satiety center, *249-250
and hypothalamus function, *840

GONADS
dysgenesis
and diabetes and Turner's syndrome, *189

GOUT
and Launois-Bensaude adenolipomatosis, *508

GRIMELIUS' SILVER METHOD, *708

GROWTH HORMONE
and ACTH and glucocorticoids, *776
and adipose tissue lipogenesis, *637
and adipose tissue response to insulin during starvation, 46-50
antilipolytic effects of, *313
and arginine infusion in newborn infants, *713
and carbohydrate metabolism, 159
and cortisone-induced hyperinsulinemia, *124
and diabetes control, *565
and diabetic angiopathy, *188
and hypoglycemia, *365
and hypophysectomy
and glucose tolerance, *712
and ketoacidosis, *184

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

and lipolysis
and protein synthesis, *506-507
and obesity in children, *183
and plasma glucose and free fatty acids flux rates, *311-312
and plasma glucose and free fatty acid metabolism in dogs, *124
and proline hydroxylation, *842
release
and acromegalic plasma, *358-359
and cirrhosis, *372-373
release during sleep, *565
and juvenile diabetes, 691-694
resistance
and antibodies, *777
responses
arginine-induced, *251-252
and diabetes with Turner's syndrome, *189
response to hypoglycemia
and dwarfism and mental retardation, *185
response to insulin-induced hypoglycemia
and weight loss in obese subjects, 87-90
and retinopathy, *345
secretion
and arginine and diethylstilbestrol, *560
and diencephalic syndrome, *189
and glucagon, *346-347
and hepatoma and hypoglycemia, 607-613
and thyroidal radioiodine uptake, *124
and unstable diabetes, *343-344
and ventromedial hypothalamic lesions, *250
and weight reduction, triiodothyronine, and diethylstilbestrol
and obesity, *315

GUANASINE 3'5'-MONOPHOSPHATE
and liver glycogenolysis, *561
and rat renal cortical glucose and ammonia production, *123

GUINEA PIGS
glucose assimilation studies, 519-521

H

HAMSTERS. *See also* Chinese hamsters
and carbohydrate metabolism and heat acclimation, *708

HEARING. *See* Auditory system

HEART
aorta
regulation of polyol pathway activity in, *329
aorta sulfate uptake
and pancreatectomy and hypophysectomy, *59
failure
and hyperosmolar nonketotic coma, 228
fetal rat
alpha-amino-isobutyric acid accumulation by, *351
function
in starved and acclimated mice, *709
glycerides and glycogen
and insulin, *778
and hyperlactatemia, *312
and malate-aspartate shuttle
and citric acid cycle, *444
peptide chain initiation
and insulin and diabetes, *335

HEART DISEASE
and diabetes mortality, *317
and ketoacidosis mortality, *347-348
mortality study, *381

HEMOCHROMATOSIS
and diabetic retinopathy, 766-770

HEMOLYTIC-UREMIC SYNDROME, *778

HEPARIN
and lipoprotein lipase, 660
and venous thrombosis in hyperosmolar coma, 308

HEPATOMEGALY
and liver glycogen, *713

HEREDITY
and diabetes
and Chinese hamsters, *356
and Friedreich's ataxia, *123-124
and Klinefelter's syndrome, *184-185
and galactosemia, *636
and glomerulopathy in mice, *370-371

HEXOKINASE
and energy cost of gluconeogenesis, *318

HEXOSE
uptake
and glucocorticoids, *507

HEXOSEDIPHOSPHATASE
in streptozotocin-diabetic rats, 71-77

HEXOSEMONOPHOSPHATE DEHYDROGENASES
and diet, 738, 744

HEXOSEMONOPHOSPHATE SHUNT
and diet, 728

HEXYLENE-GLYCOL
and insulin release, 257-258

HISTIDINE
and glucagon secretion, *710

HOLOCAINE
and insulin secretion, 723-724

HOMOCYSTINURIA
and pyridoxine, *778

HORMONES
of anterior pituitary gland, *384
and carbohydrate metabolism, 159-160
and diabetic pregnancy, 696-704
and gluconeogenesis and glycogenesis, *312
glucoregulatory
and 2-deoxy-D-glucose, *711
and hypothalamus function, *840
and insulin production, *182
and insulin secretion, *843
in obese adolescents, 802
intestinal
and insulin secretion, *185, *445, *712
and pancreas insulin levels, *124

polypeptide
and glucagon secretion, *341
and pyruvate dehydrogenase, *444
and reactive hypoglycemia, *373-374
and RNA labeling, 12
-substrate relationships to plasma lipid levels
in prediabetic and normal males, *371

HYALINE MEMBRANE DISEASE
and diabetic pregnancy, *355

HYDRAZINE
and insulin release, *840

HYPERALANINEMIA
and exercise-induced hyperglucagonemia, *339

HYPERCHOLESTEROLEMIA
and blood lipids, *713

HYPERGLUCAGONEMIA
and diabetes, 838
exercise-induced, *339
and ketoacidosis, 837

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

HYPERGLUCEMIA
and hyperosmolar nonketotic coma, *776

HYPERGLYCEMIA
and adrenalectomy, 132
and L-asparaginase, *253
and carbohydrate metabolism
and hypoglycemic agents, *840
in comparison of diabetes screening methods, 112-115
and coronary heart disease mortality, *381
in diabetic *Mystromys albicaudatus*, *123
and diet, *709
diphenylhydantoin-induced
and insulin release, 177-181
and exercise, *339
fasting
in maturity-onset diabetics, 45
and glucagon-mediated growth hormone release, *346-347
and growth hormone release during sleep, 691-694
and hemochromatosis, 766
and hyperbaric-hyperoxia, 284-285
and hyperosmolar coma, 228
and hypophysectomy and sympathectomy, 674
and insulin, 422-423
insulin-induced post-hypoglycemic and "brittle" diabetes, *310
and insulin secretion, *323
and intracranial pressure and polyol accumulation, *843
and mannoheptulose, 456
nonketoacidotic
and diazoxide therapy in uremia, 501-503
and obesity
and insulin resistance, *710
and pancreas insulin secretion, *323
and PIDH, 734-737
and Pima Indian diabetes survey, 756-765
and progesterone, *254
and streptozotocin, 513

HYPERGLYCERIDEMIA
and carbohydrate intolerance, 214

HYPERINSULINEMIA
cortisone-induced
and growth hormone, *124
and diabetes
in Pima Indians, *348
and DNA synthesis, *253
and glucose intolerance
and scleroderma, *354
and hypoglycemia in infancy, *249
and hypophysectomized rats bearing hypothalamic lesions, *444
induced by diabetogenic bovine pituitary peptide, *711
and mazindol and d-amphetamine, *844
and obesity, 107
and pancreas beta-cell replication, *841

HYPERKETONEMIA
and starvation
and pregnancy, *507

HYPERLACTICACIDEMIA
and ethanol-phenformin synergism, *324
reversible, *312

HYPERLIPEMIA
and capillary blood flow, *122
and dietary fat and carbohydrate, 833
and glycerides and lipoproteins, *126
and low sugar intake, *443

HYPERLIPIDEMIA
and coronary heart disease mortality, *381
and hemolytic-uremic syndrome, *778
and obesity, *712

HYPERLIPOPROTEINEMIA
and carbohydrate metabolism, *362
and cutaneous xanthomatoses, *316
and diet, *250
and dietary carbohydrates and fats, *249, *310
and Launois-Bensaude adenolipomatosis, *508
and prediabetic males, *371

HYPERPHAGIA
and insulin sensitivity, *318

HYPERPLASIA
islet cell
and insulin sensitivity, *336-337

HYPERPNEA
and pneumomediastinum, *357

HYPERSECRETINEMIA
and diabetes, *322

HYPERTENSION
and cirrhosis
and diabetes, *708
and diabetes mortality, *317
and diet, *709
and glucose tolerance
and diuretic therapy, *842-843
and hyperosmolar nonketotic coma, 228
risk factors, *506
and vascular disease
and diabetes, *370

HYPERTRIGLYCERIDEMIA
carbohydrate-induced
and phenformin, 739-743
and diet, 755
and latent diabetes, *359-360
and obesity
and insulin and triglyceride levels, 664-671
and serum insulin study, *122
and serum lipids and lipoproteins, *362
in weanling hypothalamic obese rats, 655-662

HYPERURICEMIA
and lactic acidosis, *318

HYPOAMINOACIDEMIA
and fasting hypoglycemia in pregnancy, *338

HYPOBARIC-HYPEROXIC ENVIRONMENT
and glucose tolerance, 282-285

HYPOCALCEMIA
and plasma calcium, glucose and immunoreactive insulin, *382-383

HYPOGLYCEMIA
and adipose tissue extracts, *707
alimentary, *58, *344
asymptomatic
in high-risk infants, *508
in children, *311, *507
chlorpropamide-induced
and insulin and growth hormone, *365
and diabetic ketoacidosis, 497
and diarrhea and monosaccharide intolerance in infants, *315
and diazoxide
and hyperosmolar nonketotic coma, *635
and encephalopathy and fatty degeneration of viscera, *564
ethanol-induced
and thyroxine, *254
and fasting
and pregnancy, *338
and glucosamine, *340
and glucose metabolism
in cows, *710-711

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

and growth hormone, *183
and hyperinsulinism in infancy, *249
in infants, *122
insulin
and fasting, *707
and insulin and growth hormone, *311-312
insulin-induced
and myxedema, *446
and plasma immunoreactive insulin response to arginine, *777
in sheep fetus in utero, *312
and weight loss in obese subjects, 87-90
and insulin secretion, 607-613
and islet cell adenoma, *843-844
and islet-cell tumor in newborn infant, *186
ketotic
and hypopituitarism, *637
and liver carcinoma
and glucagon therapy, *316
neonatal
and sulfonylurea drugs during pregnancy, *314
and neonatal infections, *713
in newborn infants
and birth weight and gestational age, *778
and congenital islet cell adenoma, *635
and plasma renin activity in dogs, *316
and proinsulin levels, *353
and quinolinic acid, *367
reactive
diagnosis of, *352
and hormonal responses, *373-374
and plasma insulin, 435-442
in women, 428-433
renin response to
and adrenergic blocking agents, *309
serum growth hormone response to
and adolescence, *185
spontaneous
and diabetes and renal insufficiency, *310
sporadic
and urine epinephrine, *636
and starvation
and pregnancy *507
and sulfonylureas, *356
and temporal lobe epilepsy, *375
and tumors, *122

HYPOINSULINEMIA
and diabetes
in Pima Indians, *348
and starvation
and pregnancy, *507

HYPOLIPACIDEMIA
and insulin and growth hormone, *311-312

HYPONATREMIA
and uremia, 501-503

HYPOPHYSECTOMY
and adipose tissue response to insulin during starvation, 46-50
and aortic sulfate uptake, *59
and glucose and galactose absorption from small intestine, *562
and glucose tolerance, *712
and hypothalamic lesions
and hyperinsulinemia, *444
and retinopathy, *345
and skin capillary resistance measures, 297-300
and ventromedial hypothalamic lesions, *250

HYPOPHYSIS
and growth hormone release
and age, *252

HYPOPITUITARISM
and growth hormone administration, *124
and growth retardation, *637
and ketotic hypoglycemia, *637
and nicotinic acid
and plasma growth hormone, free fatty aids and glucose, *562-563

HYPOTENSION
and ketoacidosis mortality, *347, 492
and tolbutamide, *383

HYPOTHALAMUS
and electrically-induced readiness to gnaw, *841
function
and exercise, lactate, hormones and gold thioglucose lesions, *840
and hypertriglyceridemia, 655-662
lesions
and diet, *505
and streptozotocin, *384
satiety center
and insulin, *249-250
and streptozotocin diabetes, *357-358

HYPOTHERMIA
and diabetic coma, *366-367
and immunoreactive insulin release and alpha-adrenergic inhibition, *776-777
and insulin secretion, *249

HYPOTHYROIDISM
and growth hormone administration, *124
and insulin release, *376

HYPOXIA
and brain glucose and lactate, *254
and infant hypoglycemia, *778
and pancreatic islet metabolism, 598-605

I

IMIDAZOLE
and insulin secretion, 457-465

IMPOTENCE
and carbohydrate tolerance, 559

INFANTS
and asymptomatic hypoglycemia, *508
birth weights
and maternal diabetes and prediabetes, *376
and chronic lactic acidosis, *121
and circadian periodicity of blood amino acids, *59
of diabetic mothers, *355
of diabetic mothers
and neonatal hypoglycemia, *314
and diarrhea
and monosaccharide intolerance and hypoglycemia, *315
and hypoglycemia
and congenital islet cell adenoma, *635
and hyperinsulinism, *249
and infection, *713
and pancreatic islet study, *122-123
large
and maternal glucose tolerance tests, 483

newborn
and glucose loading and arginine infusion, *713
and hypoglycemia study, *778
and islet-cell tumor, *186
and pancreas islet cell adenoma, *843-844

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

overweight
and intravenous glucose tolerance, *123
premature
and plasma immunoreactive insulin, 590
and serum insulin responses, *358
and pseudotumor cerebri in galactosemia, *121

INFECTIONS
and diabetes, 162
and diabetic ketoacidosis mortality, 493
with encephalomyocarditis virus
and diabetes-like syndrome in mice, *561
and hypoglycemia, *713
and insulin secretion
and obesity, *382
and insulin utilization, 795-796

INSULIN
A and B chains, *377
and C-14-acetate and S-35-sulfate uptake into aortic mucopolysaccharides, *312
action
and fatty acid synthesis, *444
and obesity, *336
administration
by aerosol, 552-556
allergy to, *563
and sheep insulin, 774-775
and amino acid transport in bone, *842
and amino acid uptake by muscle, *60
antagonism
and albumin, *309
and pituitary gland hormones, *384
antibodies to, *505-506
and proinsulin, *446
and Arthus reaction with lupus erythematosus cell phenomena, *445
basal
and adrenergic receptors, *322
binding to plasma membranes, *340-341
biosynthesis
in diabetic mice, 677-684
and islets of Langerhans, 258-259, 263-264
bonito
and insulin secretion in dogs, *60
and carnitine-C-14 metabolism, *445
catabolism
and kidney failure and anephric state, 467-474
and choline
and glycogen synthesis, *369
and C-14-O_2 production by skin fibroblasts, *383
content
of fetal endocrine pancreas, *381-382
of single pancreatic rat islets, *327
coupling with ethyl clycinate and l-ethyl-3 carbodi-imide, *316
deficiency
and protein synthesis, *373
degradation
and insulin-specific protease, *342
-dependent diabetes
and hyperglycemic nonketotic coma, *561
dinitrophenyl
antibodies induced by, *315
and diuretics, *843
and DNA synthesis, *253
dosage
and blood and urine glucose and acetone bodies, *182
and ketoacidosis, 491
and remission of juvenile diabetes, *361
effects on isolated fat cells, *187-188
and epinephrine, *187
and ethyl glycinate
and l-ethyl-3-carbodi-imide, *60
and fat cell receptor inactivation by trypsin, *184
-glucagon ratio
and catabolic diseases, 834-837
and glucokinase, 213
and glucose turnover, *841
and glucosyltransferase, 644-645
glutaraldehyde
and antibodies to insulin, *710
and glycogen synthetase, *844
and heart glycerides and glycogen
and alloxan diabetic rats, *778
and heart and muscle peptide-chain initiation, *335
and hepatic enzymes in streptozotocin-diabetic rats, 73-77
and hypothalamic satiety center, *249-250
immunoassays
by back-titration, 33-44
in primates, *315
and proinsulin, *372
and serum insulin and plasma insulin, *313
immunoreactive
and alpha-adrenergic inhibition of release during hypothermia, *776-777
and chemical diabetes in children, *124
in portal and peripheral venous blood after tolbutamide administration, 686-690
and secretin, *322
and sorbitol, *377-378
and tolbutamide administration, 168-170
-induced fat atrophy
treatment, 628-631
-induced hypoglycemia
in sheep fetus in utero, *312
-induced posthypoglycemic hyperglycemia
and brittle diabetes, *310
inhibition
and insulin secretion, 1-9
iodination study, *315
knowledge of, 55
and leucocyte migration tests, 426-427
levels
and reactive hypoglycemia, *352
-like activity
nonsuppressible, *251
and lipogenesis, *379
and liver glucose metabolism
and tolbutamide, *337
and liver glucose-6-phosphate dehydrogenase, 815, 823
and liver steatosis, *309
and maltose, *254
and mammary gland metabolites, *636
and D-mannoheptulose infusions, *508
and meal ingestion in rats, *254
metabolism
and glutathione-insulin transhydrogenase, *342
and potassium chloride, *443
and metyrapone, *313
and muscle carbohydrate and palmitate metabolism, *840
and muscle paralysis, *250-251
neutral and biphasic
and fat atrophy treatment, 628-631
neutral regular, *361-362
newly synthesized
and secretion from isolated rat islets, *334
from normal and diabetic human pancreas
and RNA labeling, 10-13
physiology in man, 785-798
and plasma glucose and free fatty acids flux rates, *311-312

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

porcine
clearance in rat liver, *252
porcine
degradation by rat adipose tissue, 276-281
portal vein
and diabetes, 286-288
production
and chorionic somatomammotropin, *182
and exercise and obesity, *183
and proinsulin
in human forearm, *333-334
proinsulin contamination of
and insulin antibodies, *314
proinsulin conversion to, *332, *335
and pyruvate dehydrogenase, *444
radioimmunoassays
wick-chromatography method, 2-4
and rat heart metabolism, *351
rat muscle
protease specific for, 140-144
regulation
and liver, *341-342
release
arginine-induced, *777
and autonomic nervous system, 78-81
and catecholamine action, *561-562
and chlorpromazine, *345-346
and cirrhosis, *372-373
and diphenylhydantoin-induced hyperglycemia, 177-181
and 2,3-diphosphoglycerate, *328
and epinephrine and alkaline earth cations, *445
and epinephrine and mannoheptulose, *188
and ethanol, *354-355
from fetal pancreas, *326-327
from fetal rat pancreas, 592-596
glucose-induced, and microtubular microfilamentous system, 257-264
from human fetal pancreatic islets, *185
and hydrazine, phenelzine and pargyline, *840
and hypothyroidism, *376
and mannoheptulose, *122
and maturity-onset diabetes, *349-350
and perfused rat pancreas islets of Langerhans, *327-328
and pork intestine extracts, *189
and pregnancy, *350-351
and prostaglandins, *374
from rat pancreas, *182, *365
and sex differences, *378-379
and sodium acetoacetate infusion, *321-322
and sulfhydryl-binding reagents, *382
and sulfonylureas, *378
and tolbutamide, *364-365
requirements
and diet, 633-634
resistance
and antibodies to insulin, *344
and glucose metabolism, *58
and obese, hyperglycemic mice, *710
and pituitary peptides, *711
and progeria, *564
and single component insulins, *352
and urine polypeptides of lipoatrophic diabetics, *315
response
in adipose tissue during starvation, 46-50
and fat cell sialic acid, *336
response to glucose, *183
and glibenclamide therapy, *360
and prediabetes, *376
of obese diabetic and nondiabetic fasting subjects, 222-223
and oral contraceptives, *187
and prediabetes, *364
and uremia, *565
response to amino acids
and 2-deoxy-D-glucose and mannoheptulose, *366
response and sensitivity
in adipose tissue and muscle of obese hyperglycemic mice, 522-534
response to sucrose or glucose-fructose
and obesity, *377
-secreting islet cell tumors
and plasma proinsulin studies, *334-335
secretion, *315
and adipose tissue fat cell size and number, 65-69
and adrenergic receptors, *309
and alimentary hypoglycemia, *344
and anorexia nervosa, *360-361
arginine-induced, and glucose, 171-176
and autonomic nervous system, *340
and autotransplanted pancreas, *560
and bonito insulin, *60
and catecholamine precursors, *312-313
cephalic phase in obese adolescents, 800-802
conditioned tolbutamide-like, *383-384
and duodenal mucosa, *185
feedback inhibition of insulin on, 1-9
and galactose, *317
and gastrin, *710
and glucose and free fatty acids, 45
and glucose, glucagon, 3'5' adenosine monophosphate, theophylline, imidazole and phenoxybenzamine, 457-465
and glybenclamide, 749
and hormones and blood flow, *843
and hepatoma and hypoglycemia, 607-613
and hypothalamic damage, *384
and hypothermia, *249
and intestinal hormones, *712
and intestinal hormones and exocrine pancreas, *507
and islet-cell carcinoma, *334
and L-leucine, *508-509
and local anesthetics, 721-727
and low-sugar diet in hyperlipemic subjects, *443
and malnourished children, *121-122
methodological approaches to studies on, *186
and methylprednisolone, *327
and methysergide maleate, *321
in neonatal and adult mice, 134-138
and obesity and infection, *382
and octanoate, *372
by ovine fetus, *776
and pargyline and mebanazine, 266-270
and portacaval shunting, *840-841
and protein-calorie malnutrition, 542-550
and pyridine nucleotides, *844
and secretin, *445
stepwise stimulation of, *323
and streptozotocin, 513-517
in thoracic duct lymph of dog, *251
and tolbutamide absorption, *505
and tolbutamide, leucine and arginine, 449-455
and tri-hydroxymethyl-aminomethane, *561
sensitivity
and diabetic coma, 246-248
and high-protein diet, *310
and mildly abnormal glucose tolerance, *707
of rat adipose tissue and diaphragm, *318
and suppression of islet cell hyperplasia, *336-337
and serum growth hormone, *562

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

"single-component"
and insulin resistance, *352
storage site, *443
tolerance tests
after fasting, *707
transport, *60
-treated diabetes
and serum insulin levels, *368
and triglycerides
and hypertriglyceridemia and obesity, 664-671
and triglyceride synthesis, *347
uptake and excretion by kidney
and kidney disease, *251
uptake in liver
and sulfonylureas, *564

I-131-INSULIN
disposition
compared with I-131-proinsulin, *333
in insulin immunoassay, 34
uptake
and growth hormone, *124

INSULINEMIA
and infantile and juvenile diabetes, *188

INSULITIS, *341

ISLETS OF LANGERHANS, *252
acid phosphatase activity, 385-387
and autonomic nervous system
and glucagon and insulin release, 78-81
beta cells
peroxidase uptake, *60
and diabetic *Mystromys albicaudatus*, *123
and glucose-induced insulin release, 257-264
insulin secretion
and local anesthetics, 721-727
and streptozotocin, *513-517
lymphocytic infiltration of, *341
methodological approaches to studies on, *186
of perfused rat pancreas
and glucose and insulin release, *327-328
and proinsulin synthesis, *332
rat
and insulin release and prostaglandins, *374
and newly synthesized insulin and proinsulin secretion from, *334

ISOPROTERENOL
and insulin and glucagon secretion, 79

J

JOSLIN QUARTER CENTURY VICTORY MEDAL, *125

K

KETOACIDOSIS
and acetone, *252
and alpha-cell function, 296
case reports, 490-499
and growth hormone, *184
and hyperglucagonemia, 837
and insulin, 797
and insulin allergy, 774-775
and insulin hypoglycemia, *707
and insulin sensitivity and release, 246-248
and liver metabolism, *359
management, *125
and mortality, *347-348
and respiratory response, *363-364
and serum C-peptide immunoreactivity, *335
and sickle cell disease, 771-773
and urinary calcium excretion, *59-60

KETOGENESIS
and glucose production, *323-324

α-KETOGLUTARATE
glucose production
and cyclic GMP, *123
and kidney gluconeogenesis, *337

KETONE BODIES
and free fatty acid metabolism, *250
3-hydroxybutyrate and acetoacetate
and diabetes, 485-488
and starvation-induced hyperketonemia, *321-322

KETONEMIA
and glucocorticoids, 96-97
and hypophysectomy and sympathectomy, 674

KETONURIA
and insulin dosage, *182

KETOSIS
and hypoglycemia
and hypopituitarism, *637
and pregnant rats, *184

KIDNEY
basement membranes
and microangiopathy study, *126
ultrastructure studies, *443-444
cortex
glucose and ammonia production study, *123
disease
and diabetes mortality, *317
and hyperosmolar nonketotic coma, 228
and hypertriglyceridemia, *778
and kidney insulin uptake and excretion, *251
estriol clearance
and complicated pregnancies, *311
failure
and blood sugar and serum insulin response to glucagon, *252
and insulin catabolism, 467-474
function
and liver function, *777
glomerular basement membrane
glucosyltransferase, and diabetes, 641-647
glomerulosclerosis
in diabetic children, 622-625
in mice, *370-371
gluconeogenesis
and phenformin, *337
glucose production
in dogs, *124-125
and fructose, 197
glycolysis
and diabetes, *346
glycosuria
and hypoglycemia, 435
and reactive hypoglycemia, 437
insufficiency
and spontaneous hypoglycemia, *310
insulin and proinsulin disposition, *333
metabolism
and diet, 396, 585, 728, 733
α-methyl glucose uptake
and temperature, *711
naturesis of fasting sites, *565
nephropathy
in sucrose-fed rats, 803-809
and nicotinic acid, *355
protein synthesis
and insulin deficiency, *373
ribosomal protein synthesis
and diabetes, 649-654
and sickle cell disease, 772
and streptozotocin-induced diabetes, *712
unilateral renal vein thrombosis, 308

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

uremia
and glucose metabolism, *562
weight
and prediabetes, *356

KIMMELSTIEL, PAUL, 117-118

KIMMELSTIEL-WILSON DISEASE
and alpha cell function, 296

KWASHIORKOR
and insulin secretion, 542-550

L

LACTATE
conversion to glucose
and tumors, *122
and hypothalamus function, *840
and kidney gluconeogenesis, *337
metabolism
and mitochondria, *508

LACTATION
and alloxan diabetes, *636

LANTHANUM HYDROXIDE
and kidney basement membrane studies, *443-444

LAUNOIS-BENSAUDE ADENOLIPOMATOSIS
and gout and hyperlipoproteinemia, *508

LESIONS
bladder
and juvenile diabetes, *709
central nervous system
and chronic lactic acidosis of infancy, *121
of central nervous system
and glucose response in juvenile macaque monkeys, 159-160
gold thioglucose
and hypothalamus function, *840
hypothalamic
and diet, *505
and hyperinsulinemia, *444
and hypertriglyceridemia, 655-662
and obesity and streptozotocin, *384
osseous
and diabetic neuropathy, 302-307
renal
in mice, *370-371
of toe nailfold capillaries
and diabetes, *311
ventromedial hypothalamic
and adipose tissue metabolism in rats, *250

LEUCINE
action
and 2-deoxy-d-glucose, *366
incorporation into muscle and cartilage protein, *446
and insulin secretion, 449-455
and plasma insulin and blood glucose and ethanol pretreatment, *354-355

L-LEUCINE
and insulin hypersecretion in obese children, *508-509

LEUCOCYTE MIGRATION TEST, 424-427

LEUCOCYTES
uremic, *565

LEUKOPLAKIA
glycogen content, *445

LIDOCAINE
and insulin secretion, 724

LIPEMIA
and capillary blood flow, *122
and carbohydrate intolerance, 214
and hypophysectomy and sympathectomy, 675

LIPIDS
adipocyte
and nutrition, *506
glucose conversion to, *315-316
metabolism
and diet, 755
and hyperosmolar nonketotic coma, *776
and kidney disease, *778
and Wolman's Disease, *187

LIPOATROPHIC DIABETES
and isolation of diabetogenic polypeptide from urine, *315

LIPO-FUNDIN
and capillary blood flow in rabbits, *122

LIPOGENESIS
and glucose loading, *711
and growth hormone, *637
by insulin, *379
in mammalian tissues, *317

LIPOLYSIS
basal
and fat-cell volume, *563-564
and cyclic AMP, *349
and free fatty acid and ATP levels in adipocytes, *309
and growth hormone, *313
and protein synthesis, *506-507
and triiodothyronine, *183

LIPOPROTEIN
and diabetes complications, *378
polyvinylpyrrolidone column fractionation, 658-659
and serum tri-, di-, and monoglycerides, *126

LIPOPROTEIN LIPASE
and hypothalamic lesions, 660

LIVER
adenosine 3',5'-monophosphate
and glucagon, 129-133
alcohol dehydrogenase, *187
amino acid uptake study, *183
carbohydrates
and glucagon, *444
carcinoma
and glucagon therapy, *316
and cholesterol metabolism, *59
cirrhosis
and diabetes, *708
cyclic nucleotides metabolism, *310
enzymes, *712
and glycogen storage disease, *125
and streptozotocin diabetes in rats, 71-77
fatty
and diabetes, *309
and somatotrophin action in pancreatectomized - sympathectomized dogs, 673-676
and L-fucose dehydrogenase, *369
function
and kidney function, *777
glucokinase
and biotin, 632
in hyperthyroid mice, *254
gluconeogenesis
energy cost of, *318
and ethanol, *324
and high-protein diet, *353-354
gluconeogenesis and glutamine metabolism,
and acidosis, *325
glucose and fructose metabolism, 195-196

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

glucose metabolism
and chronic tolbutamide treatment, *337
glucose-6-phosphatase
in rats, 518, 551
glucose-6-phosphate dehydrogenase
and carbohydrate and insulin, 815, 823
glycogen
and high-protein diet, *310
in Indian diabetics, *713
and infant hypoglycemia and diarrhea, *315
in obese hyperglycemic mice, 535-540
and odd-carbon fatty acids diet, 203-204
and phenformin, *561
glycogenolysis and glyconeogenesis
and renal insufficiency with spontaneous hypoglycemia, *310
glycogenosis, *125
glycogen turnover, *713
hepatoma
and insulin secretion, 607-613
hexosemonophosphate shunt dehydrogenase
and diet, 738, 744
insulin
and ribose, *562
insulin extraction, *341-342
and insulin mechanism, 791-792
lipid metabolism, 755
lipids
and glucagon infusion, *121
and streptozotocin diabetes, *354
and Wolman's disease, *187
lipoproteins
and obesity, *712
metabolism
and age and strain in rats, 518, 551
in diabetic rats, *346
nicotinamide adenine dinucleotide
and streptozotocin, 513
perfused rat
and acidosis, *325
and glucagon bioassays, *317
and glycogenolytic activity of cyclic 3′,5′-monophosphates, *188
and guanasine 3′5′-monophosphate, *561
and pyruvate recycling during gluconeogenesis, *507
and sulfonylureas, *564
perfusion
and insulin antagonism of albumin, *309
and proinsulin and insulin disposition, *333
protein
of diabetic and fasted rats, *708
rat
and diet and gluconeogenesis, 577-584
and gluconeogenesis, *324-325
and glucose and fructose metabolism, *637
glycogen synthesis, *369
and insulin, proinsulin and peptide clearance, *252
and RNA synthesis, *841
ribosomes
protein synthesis, effect of diabetes on, 27-32
weight
and prediabetes, *356

LYMPHOCYTES
stimulation
and glucagon, *446

LYSINE-VASOPRESSIN
and glucagon release, *187

M

MAGNESIUM
and insulin release, *445

MALNUTRITION
and glucose tolerance and insulin secretion in children, *121-122
protein-calorie
and insulin secretion, 542-550

MALTATE-ASPARTATE SHUTTLE
and citric acid cycle
in rat heart mitochondria, *444

MALTOSE
and insulin, *254

MAMMARY GLANDS
and alloxan diabetes, *636
metabolites
and insulin and anti-insulin serum, *636

MANDIBULAR ALVEOLAR MUCOSAE
of diabetic children, *313

D-MANNOHEPTULOSE
and blood glucose and insulin levels, *508
and calcium uptake by islets of Langerhans, 261-262
and 2-deoxy-d-glucose
and insulin response to amino acids, *366
and glucose-stimulated insulin release, *188
trial in man, *122

MANNOHEPTULOSE-C-14
metabolism in rat, 456, 466

MARASMUS
and insulin secretion, 542-550

MAZINDOL
and hyperinsulinemia, *844

MEBANAZINE
and insulin secretion, 266-270

MECHOLYL
and insulin secretion
and holocaine and propranolol, 724

MENSTRUATION
and growth hormone responses, *252

MENTAL ILLNESS
and islet-cell tumors, *313

MENTAL RETARDATION
and diet, *709
and dwarfism
and growth hormone, *185
and galactosuria screening tests, *250

MEPIVICAINE
and insulin secretion, 725

METABOLISM
acetate, propionate, butyrate, and glucose
by bovine cerebral cortex slices, *509
adipose tissue
and diet, *348-349
and hypothalamus, *357-358
and theophylline and dibutyryl cyclic AMP, *380
and ventromedial hypothalamic lesions, *250
amino acid, *351
carbohydrate
and arteriosclerosis, *362
and L-asparaginase, *253
and heat-acclimated hamsters, *708
and liver insulin, *562
and 1-methyl-4 pyridinium chloride and phenformin, *840
and myocardial infarction, *564
in myocardium, *252
and potassium depletion, *508
and respiratory gas exchange, *564

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

and scleroderma, *354
and carbohydrate-free diets, *314, *343
carbohydrate and palmitate
in skeletal muscle, *840
carnitine-C-14, *445
cholesterol, *59
and cortisone glucose tolerance tests, *637
and fasting in obese diabetic and nondiabetic subjects, 214-225
fatty acid
in diabetic rat testicles, *123, *189
and migraine, *778
free fatty acid
and ketones, *250
fructose and sucrose
and age and strain in rats, 518, 551
glucose, *58
and adrenergic receptors, *843
and chronic acceleration, *312
and diabetic pregnancy, 696-697
and ganglionic blocking agents, *381
and glucoregulatory hormones, *711
and rat pancreatic islets, *710
and starvation, 46-50
and uremia, *562
glucose and fructose, 195-196
in rat liver, *637
glucose and insulin
and estriol and estradiol, 271-275
and jejunoileostomy, *124
in perfused rat pancreas, *327-328
and potassium chloride, *443
and glucose loading, *711
glutamine
and acidosis, *325
and glybenclamide, 745-754
glycerol
in neonatal rat, *126
glycogen, *713
by lean and obese mouse pancreas, *379-380
and hyperosmolar nonketotic coma, 228-237
insulin, 785-798
and glutathione-insulin transhydrogenase, *342
kidney
and diet, 396, 585, 728, 733
lipid
and diet, 755
lipid and carbohydrate
and hyperosmolar nonketotic coma, *776
liver
and diabetic ketoacidosis, *359
and sulfonylureas, *564
liver glucose
and tolbutamide, *337
and low carbohydrate diet, *253
maltose
and insulin, *254
mammary tissue
and alloxan diabetes, *636
mannoheptulose-C-14, 456, 466
and nonketotic hyperosmolar coma, *253
in obese hyperglycemic mice
and insulin, 522-534
and plasma free fatty acid, immunoreactive insulin and liver glycogen, 535-540
and obese and muscular overweight, *842
palmitate
and diabetes, *359
pancreas islet
and tolbutamide, *364-365
phenformin
and high altitude, *561
plasma glucose and free fatty acids
and growth hormone, *124
protein
and lipemia, *329-330
pyruvate and lactate
and adipose tissue mitochondria, *508
in rat pancreas islets and tolbutamide and hypoxia, 598-605
RNA
and diet, 738, 744
and sorbitol, *377-378
thiamine
and chronic lactic acidosis of infancy, *121
and weight loss in obese subjects, 83-90
zinc
and diabetes, 206-212

α-METHYL GLUCOSE
uptake by kidney cortex
and temperature, *711

METHYLPREDNISOLONE
and pancreas beta-cell replication, *327

1-METHYL-4-PYRIDINIUM CHLORIDE
and carbohydrate metabolism, *840

METHYSERGIDE MALEATE
and insulin secretion, *321

METYRAPONE
and diabetes, *313

MICE
alloxan diabetic and normal
and antibody responses, 162-166
and anti-insulin serum, *346
diabetic
and diet and pancreas beta cells, *841
and hypothalamus function study, *840
and retinal angiopathy, *314
and encephalomyocarditis virus
and diabetes-like syndrome, *561
fibroblasts
RNA labeling and normal and diabetic human insulin in, 10-13
and glomerulopathy
and genetics and environment, *370-371
and growth hormone studies, *124
and hyperglycemia
and hypoglycemic agents, *840
hyperthyroid
and hepatic glucokinase and glucose-6-phosphatase activities, *254
and hypoglycemic effect of adipose tissue extracts, *707
and insulin action on hypothalamic satiety center, *249-250
and insulin biosynthesis
and hereditary diabetes, 677-684
and insulin tolerance tests, *707
neonatal and adult
glucose tolerance and insulin secretion study, 134-138
obese
and restoration of insulin sensitivity, *336-337
obese hyperglycemic
and adipose and muscle response to insulin, 522-534
and glucose tolerance, hyperinsulinemia and hyperglycemia time sequence, *184
and insulin resistance, *710
and plasma free fatty acids, immunoreactive insulin and liver glycogen, 535-540
and pancreas beta-cell replication, *327
and starvation
and glucose availability and heart function, *709

MICROANGIOPATHY
and juvenile diabetes, *563
pathogenesis of, *126

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

MICROSCOPY
electron
and basement membrane studies, *126
of beta cells, *60
and calcium migration studies, *841
of pancreas beta cells in tumor-bearing rats, 17-25
of pancreas beta cells of normal rats, 386, 387
and intravascular sickling, 772-773
of kidney basement membrane
and glomerulosclerosis in children, 622-625
light
and cellular localization of gastrin, 391-395
of pancreas beta cells in tumor-bearing rats, 16-17
light and electron
of fetal endocrine pancreas, *381-382
of islet-cell tumors, *313
and pancreas alpha-cell structure, *708
of pancreatic islet of infants with severe hypoglycemia, *122-123
and sucrose-fed rat kidney, 803-809

MIGRAINE
and blood glucose and fatty acid metabolism, *778

MINERALS. *See also under individual names of*
in foods, 139, 161

MITOCHONDRIA
giant
and *Euglena gracilis*, *777

MONKEYS
juvenile macaque
and response to intravenous glucose, 156-160
and pancreas beta-cell replication
and glucocorticoid, *327
rhesus
and glucose tolerance, plasma insulin, progesterone and estriol, 271-275
and insulin immunoassays, *315
squirrel and rhesus
plasma and pancreatic insulin in, 151-155

MONOSACCHARIDES
intolerance
in diarrhetic infants, *315

MORTALITY
and coronary heart disease
and phenformin and metabolic factors, *381
and diabetes, *316-317
and diabetic ketoacidosis, *347-348, 490-499
fetal and neonatal
and maternal ketoacidosis, 495-496
and hyperosmolar nonketotic coma, 232-233, *843
in UGDP study, *368
and vascular disease
and nutrition, *350
and venous thrombosis in hyperosmolar coma, 308

MOUTH
and oral symptoms
and glucose intolerance, *373

MUCOPOLYSACCHARIDES
aortic
and C-14-acetate and S-35-sulfate uptake, and insulin, *312

MUSCLE
abnormalities
and juvenile diabetes, *189
amino acids accumulation
and insulin, *60
biopsies
and long-term diabetes, *251
capillary basement membrane thickening
and carbohydrate intolerance, *329
and carbohydrate and palmitate metabolism, *840
and free fatty acid metabolism, *250
glucose uptake
and hepatoma, 610
glycogen
and high-protein diet, *310
incorporation of leucine, *446
insulin sensitivity and response
in obese hyperglycemic mice, 522-534
paralysis
and insulin, *250-251
peptide chain initiation
and insulin and diabetes, *335
protein metabolism
and insulin, 792-793
and protein synthesis
and diabetes, 27-32
proteolysis
and insulin, 794
weakness
and hyperlactatemia, *312

MYOCARDIAL INFARCTION
and carbohydrate-C-14 metabolism *564
and diabetes, *316
and diabetes with Friedeich's ataxia *123-124
and diabetic ketoacidosis, 493-494
and ketoacidosis, *347-348

MYOCARDIUM
carbohydrate metabolism, *252
free fatty acid metabolism, *250

MYSTROMYS ALBICAUDATUS
and diabetes, *123

MYXEDEMA
and insulin-induced hypoglycemia and vasopressin, *446

N

NAUSEA
and fluorescein retinal angiography, *311

NEGROES
and diabetes and sickle cell disease, 771-773

NEPHROPATHY
and glomerulosclerosis in children, 622
and insulin catabolism, 467-474

NERVE CONDUCTION STUDIES
and diabetic amyotrophy, *330
in streptozotocin diabetic rats, *331

NERVOUS SYSTEM
abnormalities
and juvenile diabetes, *509
autonomic
and diabetes, *331-332
and glucagon and insulin release, 78-81
and insulin secretion, *340
central and peripheral
and long-term diabetes, *251
conduction
and treatment in newly diagnosed diabetics, *318
and diabetic amyotrophy, *330
and encephalopathy with fatty degeneration of viscera, *564
and growth hormone release during sleep, *565
and hyperosmolar nonketotic coma, 228
lesions
and glucose response in juvenile macaque monkeys, 159-160

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

and meal stimulus on plasma insulin, free fatty acids and glucose, *371
and sensory perception thresholds and diabetics and their relatives, *330-331
sympathectomy and somatotrophin action, 673-676

NEUROPATHY, DIABETIC
and bladder dysfunction, *313
and foot lesions, 302-307
in juvenile diabetics, *509
in streptozotocin diabetic rats, *331
and treatment of newly diagnosed diabetics, *318

NIALAMIDE
and serum insulin, *185

NICOTINAMIDE
and streptozotocin, 513-517

NICOTINAMIDE ADENINE DINUCLEOTIDE
and insulin release, *382

NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE
and insulin release, *382

NOREPINEPHRINE
and free fatty acid levels, *309
and insulin and glucagon release, 78-81
and insulin release, *561-562

NUTRITION. *See also* Diet
and adipocyte size, lipid, and enzyme content *506
and buccal smear technic, 167
and diabetes, 633-634

O

OBESITY
and adipose tissue, *336
and adipose tissue lipogenesis, *310-311
and diabetes
and fasting, 214-225
and vascular complication, *350
and diabetes prevalence study, 99-107
and diet, *348-349
and fasting
and growth hormone administration, *184
and fenfluramine, *351
and glucose metabolism, *58
and growth hormone in children, *183
and growth hormone release in sleep, *565
and hypertriglyceridemia
and insulin and triglyceride levels, 664-671
and hypoglycemia, 435, 437
hypothalamic
and hypertriglyceridemia in weanling rats, 655-662
and insulin production
and exercise, *183
and insulin response
and adipose tissue, 522-534
and sucrose and glucose-fructose, *377
and insulin secretion, 45, 65-69
in adolescents, 800-802
and infection, *382
and insulin sensitivity, *336-337
and insulin tolerance, *707
and jejunoileostomy, *124
and L-leucine
and insulin secretion, *508-509
and liver lipoprotein production, *712
and meal stimuli
and plasma insulin, free fatty acids and glucose, *371
and metabolic effects of weight loss, 83-90
and muscular overweight
and metabolism, *842
and nicotinic acid
and plasma growth hormone, free fatty acids and glucose, *562-563
and pancreas glycogen metabolism, *379-380
and plasma free fatty acid, immunoreactive insulin and liver glycogen, 535-540
and "point diet," *253
and starvation
and calciuria, *59-60
and sulfonylurea treatment, *366
and vascular disease, *370
and weight reduction, *563
and triiodothyronine, diethylstilbestrol, and growth hormone, *315

OCTANOATE
and insulin secretion, *372

OLFACTORY SYSTEM
and plasma insulin, free fatty acids and glucose, *371

ORAL CONTRACEPTIVE AGENTS
and blood glucose
and prediabetes, *507
and glucose tolerance and insulin response, *187
and plasma lipids, *636
and lipoproteins, *317
and sexual dysfunction, 559

ORAL HYPOGLYCEMIC AGENTS
AO44, *711
and diabetic ketoacidosis, 496
and diet, *509
and hyperosmolar nonketotic coma, 228
and liver steatosis, *309
PIDH, 734-737
S 1702, *353

OSTEOPATHY
and diabetes, 302-307

OXALACETATE
and kidney gluconeogenesis, *337

OXYGEN
consumption
and triiodothyronine, *183

OXYTOCIN
and glucagon secretion, *187

P

PALMITATE
metabolism
and carbohydrate metabolism, *840
and diabetes, *359

PANCREAS
alpha cells
histochemical and ultrastructural studies, *708
alpha-cell function, 288, 296, 838, 839
autotransplantation in sheep
and insulin secretion, *560
beta cell replication
and diet, *841
and glucocorticoid, *327
beta cells
acid phosphatase activity, 385-387
calcium uptake, and cyclic AMP, *328-329
of rats with growth hormone-producing tumors, 15-25
storage site, *443
ultrastructure study, *326

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

exocrine
and insulin secretion, *712
and insulin secretion stimulation by intestinal hormones, *507
fetal
and insulin and glucagon release, *326-327
ultrastructure and insulin content, *381-382
fetal and newborn rat
and insulin response to glucose, 586-590
fetal rat, *326
and biphasic insulin release, 592-596
gastrin
cellular localization of, 389-395
glucagon secretion, *341
and arginine and histidine, *710
and exercise, *339
and glucosamine, *340
and secretin, *339
insulin
and growth hormone, *124
in normals and diabetics, 10-13
and plasma insulin, *360
of prediabetic hamsters, *356
in squirrel and rhesus monkeys, 151-155
insulinomas
and proinsulin, *842
insulin secretion
and autonomic nerve endings, *340
and biogenic monamine mechanism, *321
and blood insulin, *60
and carbohydrate, 786-790
cephalic phase, 800-802
and hormones and blood flow, *843
and local anesthetics, 721-727
and re-establishment of normoglycemia, *323
islet cell adenoma
and hypoglycemia, *249, *635
in newborn infants, *635, *843-844
islet cell carcinoma
insulin secretion study, *334
islet cell hyperplasia
and insulin sensitivity, *336-337
islet-cell tumors
and psychiatric symptoms, *313
islet stimulation
serum immunoreactive insulin levels during, 404-408
and serum immunoreactive insulin and prednisone, 410-415
islets
glucose metabolism studies, *710
in hypoglycemic infants, *122-123
insulitis, *341
permeability studies, *318
islets of anglerfish
and glucagon biosynthesis study, *338-339
mouse
and glycogen metabolism, *379-380
and nonsuppressible insulin-like activity, *251
perfused canine
insulin inhibition study in, 1-9
perfused rat
and glucose and insulin metabolism, *327-328
insulin secretion study, 449-455, 457-465
and protein-calorie malnutrition, 542
rat
and glucose response and insulin content, *327
and hypothermia and insulin secretion study, *249
and insulin release, *182, *365, *840
and insulin secretion and octanoate, *372
islet metabolism, 598-605
metabolism and tolbutamide, *364-365
and proinsulin synthesis regulation, *332

PANCREATECTOMY
and aortic sulfate uptake, *59
and infant hypoglycemia, *249
in man, *188
and somatotrophin action, 673-676

PANCREATITIS
and diabetic ketoacidosis, *347, 494

PANCREOENZYME
and insulin secretion, *507

PAPAGO INDIANS
and diabetic and prediabetic pregnancy, *375-376

PARGYLINE
and insulin secretion, 266-270, *840

PEP CARBOXYKINASE
in streptozotocin-diabetic rats, 71-77

PEROXIDASE
beta cell uptake of, *60

PHENELZINE
and insulin release, *840

PHENETHYLBIGUANIDE
and pyruvate kinase, *325

PHENFORMIN
and alimentary hypoglycemia, *344
and carbohydrate-induced hypertriglyceridemia, 739-743
and carbohydrate metabolism, *840
and coronary heart disease risk, *381
and ethanol
and hyperlacticacidemia, *324
-induced hyperlactatemia, *312
and kidney gluconeogenesis, *337
and lactic acidosis, *844
metabolism
and high altitude, *561
and PIDH, 734-737

PHENOXYBENZAMINE
and insulin secretion, 457-465

PHENTOLAMINE
and adipose tissue lipolysis, 146-150
and hypothermic inhibition of insulin secretion, *249
and insulin release, *776-777
and starvation, *343

PHENYLALANINE
incorporation into protein
and diabetes, 27-32

PHOSPHENOL PYRUVATE CARBOXYKINASE, 196

PHOSPHOFRUCTOKINASE
and biotin and insulin, 632
and energy cost of gluconeogenesis, *318
and glycolysis, 196, 197

PHOSPHOLIPIDS
and calcium migration, *841

PHOSPHORYLASE
and glycogen storage disease, *125

PHOTOCOAGULATION, *443

PIDH
and glucose-loading study, 734-737

PIGS
glucose tolerance tests in, *58
pre- and postnatal
glycolytic and gluconeogenic enzyme levels, *712

PIMA INDIANS
and diabetes
and hyperinsulinism and hypoinsulinism, *348

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

diabetes survey
and bimodality in glucose tolerance distributions, 756-765
and diabetic and prediabetic pregnancy, *375-376
and glucose tolerance tests, *374-375
and retinopathy study, *352-353

PITUITARY GLAND
ablation
and diabetic retinopathy, *345, 824-832
and retinal and optic disc vessels, *506
growth hormone
and Bovril test, *562
hormones
and insulin antagonism, *384
peptide
and induced hyperinsulinemia, *711

PLACENTA
lactogen
and diabetic pregnancy, 696-704

PLASMA
acromegalic
and growth hormone release, *358-359
calcium, glucose and immunoreactive insulin
in hypocalcemic parturient cows, *382-383
cortisol
and head injury, *364
electrolytes
in experimental diabetic hyperosmolar syndrome in rats, 95, 96
fasting glucose
and high-carbohydrate diet, *342-343
free fatty acids
and growth hormone, *124
and sodium acetoacetate infusion, *321-322
and sorbitol, *377-378
free fatty acids and immunoreactive insulin
in obese hyperglycemic mice, 535-540
free fatty acids and triglycerides
and glucagon infusion, *121
glucose
and glucagon, 130-131
in Pima Indian diabetes survey, 756-765
and retinopathy, *352-353
and weight loss, 86
glucose and free fatty acids
and insulin and growth hormone, *311-312
and weight gain in pregnancy, *363
glucose, free fatty acids and insulin
and weight loss studies, 85-86
glucose and insulin
and glybenclamide therapy, 747-749
and high-protein diet, *310
glucose, insulin, free fatty acid, and growth hormone responses
and cystic fibrosis, *445
glucose, insulin and growth hormone
and anorexia nervosa, *360-361
growth hormone
and glucose ingestion, *363
and methysergide maleate, *321
and progeria, *564
and progesterone and pregnancy, *338
growth hormone, free fatty acids, and cortisol
and reactive hypoglycemia, *374
growth hormone, free fatty acids and glucose
and nicotinic acid, *562-563
immunoreactive insulin
and arginine, *777
in malnourished children, *121
in premature infants, 590
and urine insulin, *123
and weight loss in obese subjects, 83, 86-90
immunoreactive insulin and free fatty acids
in obese adolescents, 801-802
insulin
A and B chains, *377
assay, 40-41
and estriol, 271-275
and exercise and glucose infusion, *186-187
and hypothalamic lesions, 659-660
and insulin immunoassays, *313
in insulin secretion and adipose tissue study, 66-69
and leucine, arginine and ethanol, *354-355
and mildly abnormal glucose tolerance, *707
and nicotinic acid, *355
and pancreas insulin, *360
and potassium depletion, *508
and reactive hypoglycemia, 435-442
response to glucose, 45
and D-ribose, *562
in squirrel and rhesus monkeys, 151-155
and tetragastrin, *710
insulin, free fatty acids and glucose
and visual and olfactory meal stimuli, *371
insulin and lipids
and RO 6-4563, *348
insulin response
and chemical diabetes, 416-423
and coffee ingestion, *126
and glucose loading in normal subjects, 729-732
insulin response to glucose
and glucagon and ethanol, 397-403
insulin-specific protease, *342
lipids
and fenfluramine-treated obese subjects, *351
and glucagon, *183
and glybenclamide, 751
and oral contraceptives, *636
in prediabetic males, *371
lipids and lipoproteins
and oral contraceptives, *317
lipoproteins
isolation technic, *253-254
membranes
glucagon and insulin binding to, *340-341
osmolality
in diabetic hyperosmolar syndrome study in rats, 95, 96
pre-beta apoprotein
and lipemia, *329-330
proinsulin
and insulin-secreting islet cell tumors, *334-335
and normal and diabetic pregnancy, *380-381
renin
and hypoglycemia, *316
sugar, free fatty acids, 11-hydroxycorticosteroids and growth hormone
response to hypoglycemia and vasopressin in myxedema, *446
triglycerides
in obese diabetics and nondiabetics, 223-224
uric acid
and nicotinic acid, *355

PNEUMOMEDIASTINUM
and acidosis, *357

PNEUMONIA
and ketoacidosis mortality, *347-348

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

POLYOL
accumulation
and hyperglycemia, *843

POLYOL PATHWAY
regulation in aorta, *329

POLYPEPTIDES
diabetogenic
isolation technic, *315

POLYVINYLPYRROLIDONE COLUMN FRACTIONATION
of lipoproteins in hypothalamic obese rats, 658-659

PONDERAL INDEX
and insulin secretion study, 65-69

PORTAL VEIN
insulin
and diabetes, 286-288

POTASSIUM
depletion
and carbohydrate metabolism, *508
and insulin, proinsulin, and growth hormone release
and cirrhosis, *372-373
and ketoacidosis, 491
and muscle paralysis, *250-251
and plasma renin in hypoglycemic dogs, *316

POTASSIUM CHLORIDE
and glucose and insulin metabolism, *443

PREDIABETES
and blood glucose
and oral contraceptive agents, *507
and Chinese hamsters, *356
and glucose and insulin responses, *364
and insulin release
and sex differences, *378-379
and insulin response to sucrose, *377
in males
and hormone-substrate relationships to plasma lipid levels, *371
and postpartum glucose tolerance, *375-376
and serum fucose and insulin responses to oral glucose, *376

PREDNISOLONE GLUCOSE TOLERANCE TEST
and pregnancy, *367-368

PREDNISONE
diabetogenic effects study, *776
and serum immunoreactive insulin levels during glucose tolerance tests and islet stimulation, 410-415

PREGNANCY. *See also* Pregnancy, diabetic
and diabetic ketoacidosis, 495-496
and fasting
and hypoglycemia, *338
and glucose tolerance tests, 476-483
and fetal outcome, *508
and insulin release
and glucose disposal rate, *350-351
and ketosis, *184
and plasma growth hormone response, *338
and plasma proinsulin, *380-381
and prednisolone glucose tolerance test, *367-368
and renal estriol clearance, *311
and starvation, *507
and streptozotocin diabetes, *562

PREGNANCY, DIABETIC
and fetal management, *355
and intravenous glucose tolerance tests in infants, *123
and plasma proinsulin, *380-381
and postpartum glucose tolerance, *375-376
and serum heat-stable alkaline phosphatase, *367
and serum immunoreactive placental lactogen and chorionic gonadotropin, 696-704
and sulfonylurea drugs
and neonatal hypoglycemia, *314
and weight gain
and insulin effectiveness, *363

PRIMATES
and insulin immunoassays, *315

PROGERIA
and endocrine response and sleep characteristics, *564

PROGESTERONE
and blood glucose in rats, *254
and diabetic pregnancy, 696-704
and glucose and insulin metabolism
and estriol, 271-275
and insulin production
and chorionic somatomammotropin, *182
and plasma growth hormone response, *338
and pregnant rats, *184

PROINSULIN
and antibodies to insulin, *446
clearance in rat liver, *252
conversion to insulin, *332
degradation by rat adipose tissue, 276-281
effects on isolated fat cells, *187-188
and hypoglycemia, *353
and insulin
in diabetic mice, 677-684
in human forearm, *333-334
and insulin immunoassays, *372
-like material
and insulinomas, *842
porcine
in insulin immunoassay, 34
release
and cirrhosis, *372-373
secretion
from isolated rat islets, *334
and mild diabetes, *335
stimulation of insulin antibodies, *314
synthesis, *332

I-131-PROINSULIN
disposition
compared with I-131-insulin, *333

PROLINE
hydroxylation
and growth hormone, *842
incorporation into protein, *842

PROPIONATE
metabolism
by bovine cerebral cortex slices, *509

PROPRANOLOL
and adipose tissue lipolysis, 146-150
and cyclic AMP, *349
and catecholamine release, 721
and insulin secretion, 723, *776-777
and liver adenosine 3',5'-monophosphate, 131
and oxytocin-stimulated glucagon release, *187
and D-ribose
and plasma insulin, *562
and starvation studies, *843

PROSTAGLANDINS
and insulin release, *374

PROTEASE
insulin-specific, 140-144, *342

PROTEINS
biosynthesis
and islets of Langerhans, 258-259

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

deficiency
and insulin secretion, 542-550
dietary
and diabetes prevalence, 106
and liver gluconeogenesis, *353-354
and endogenous glucose production, 836
and gluconeogenesis, 577-584
ingestion
and insulin, 790-793
in insulin immunoassay, 34
and kidney gluconeogenesis, *337
metabolism
and lipemia, *329-330
synthesis
and amino acid transport, *842
and insulin deficiency, *373
by kidney ribosomes, 649-654
and lipolytic action of growth hormone and glucocorticoids, *506-507
by liver ribosomes, 27-32
by monosomes, 29-30
by polysomes, 29

PSEUDOAPPENDICITIS
of diabetic ketoacidosis, *125

PSEUDOPAPILLEDEMA, *711

PUBERTY
and growth hormone responses, *251-252

PULSE WAVE VELOCITY
in juvenile diabetics, *563

PYRIDINE NUCLEOTIDES
and insulin secretion, *844

PYRIDOXINE
and genetic disease, *778

PYRIMIDINE
incorporation into RNA fraction of fibroblasts
and insulin, 12-13

1-(2-PYRIMIDINYL)-4-IMINO-1, 4-DIHYDROPYRIDINE HYDROCHLORIDE. *See* PIDH

PYRUVATE
and chronic lactic acidosis of infancy, *121
and insulin release
and 2,3-diphosphoglycerate, *328
from fetal rat pancreas, 592-596
and kidney gluconeogenesis, *337
metabolism
and mitochondria, *508
recycling
and gluconeogenesis in perfused rat liver, *507

PYRUVATE-3-C-14
and gluconeogenesis and glycogenesis and diet and hormones, *312

PYRUVATE CARBOXYLASE, 196
regulatory factors for, *446

PYRUVATE DEHYDROGENASE
and hormones, *444

PYRUVATE KINASE
and biotin and insulin, 632
and energy cost of gluconeogenesis, *318
and phenethylbiguanide, *325

Q

QUINOLINATE, *324-325

R

RABBITS
and diurnal variation in glucose tolerance, *707
glucose assimilation studies, 519-521
and insulin administration via aerosol, 553
and insulin response to amino acids
and 2-deoxy-d-glucose and mannoheptulose, *366
and lipemia and capillary blood flow study, *122

RACE. *See also* Negroes
and diabetes prevalence, 106-107

RAT
alloxan diabetic
and biotin and glucokinase, 632
and heart glycerides and glycogen, *778
and kidney ribosomal protein synthesis, 649-654
and lactation and mammary tissue metabolism, *636
and liver palmitate metabolism, *359
and renal glomerular basement membrane biosynthesis, 641-647
and anti-insulin serum, *346
aortic sulfate uptake
and pancreatectomy, hypophysectomy, and pancreatectomy-hypophysectomy, *59
blood glucose
and progesterone, *254
and carbohydrate-free diet, *314
carnitine-C-14 metabolism study in, *445
and conditioned tolbutamide-like insulin secretion, *383-384
diabetic
and glucokinase and biotin deficiency, 199, 213
and glycolytic and gluconeogenic enzymes, *346
and linoleic acid metabolism, *123
and protein synthesis by liver ribosomes, 27-32
and S 1702 therapy, *353
and diabetic hyperosmolar syndrome, 92-97
and diet
and electroretinograms, *561
and hexosemonophosphate dehydrogenases and RNA metabolism, 738, 744
high-protein, *310
and hyperglycemia, *709
odd-chain fatty acids, 200-204
and diurnal variation in glucose tolerance, *707
fasting
and ganglionic blocking agents and glucose metabolism, *381
and fasting hypoglycemia
and pregnancy, *338
fed and fasted
and adipose tissue metabolism study, *380
fetal and weanling
plasma and pancreas insulin studies, *360
and fructose and sucrose responses
and age and strain, 518, 531
glomerular basement membrane
and microangiopathy studies, *126
and glucosamine stimulation of pancreatic glucagon secretion, *340
and glucose assimilation studies, 519-521
and glucose metabolism studies, *710
and growth hormone-secreting tumors
and pancreas beta cell changes, 15-25
heart mitochondria, *444

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

hypophysectomized
and glucose and galactose absorption from small intestine, *562
and glucose tolerance, *712
and hypothalamic obesity
and hypertriglyceridemia, 655-662
and insulin
and C-14-acetate and S-35-sulfate uptake into aortic mucopolysaccharides, *312
and insulin antibodies, *356-357
and insulin secretion, 8
and hydrazine, phenelzine and pargyline, *840
and octanoate, *372
and pargyline and mebanazine, 266-270
and liver adenosine 3',5'-monophosphate response to glucagon, 129-133
and liver protein studies, *708
and mannoheptulose-C-14 metabolism, 456, 466
and meal ingestion
and insulin, *254
neonatal
and glycerol metabolism, *126
obese
and adipose tissue lipogenesis, *310-311
and streptozotocin, *384
pancreas beta cells
acid phosphatase activity in, 385-387
and phenformin metabolism studies, *561
and pregnancy ketosis, *184
pregnant
and insulin effectiveness studies, *363
and I-131-proinsulin and I-131-insulin disposition, *333
and single-dose of alloxan
and glucose intolerance in offspring, *637
streptozotocin diabetic
and biguanides, *711
and kidney hypertrophy, *712
and liver lipids, *354
and neuropathy, *331
and pregnancy, *562
and insulin treatment, 71-77
and sucrose diet
and nephropathy, 803-809
thyroxine-treated
and ethanol-induced hypoglycemia, *254
and vasopressin and chlorpropamide study, *58, *60
and ventromedial hypothalamic lesions
and adipose tissue metabolism, *250

RENIN
response to hypoglycemia and epinephrine
and adrenergic blocking agents, *309

RESPIRATION
and gas exchange
and carbohydrate metabolism, *564
and insulin administration by aerosol, 552-556
and ketoacidosis, *363-364

RESPIRATORY DISTRESS SYNDROME
and diabetic pregnancy, *355

RETINA
and diet, *561
fluorescein angiography
side effects of, *311
and glucose assimilation studies, 519-521

RETINOPATHY, DIABETIC, *443
absence of, *375
and diabetes duration, *251, 626-627
and diabetic pregnancy, 701-702
and glucose assimilation studies, 519-521
and growth hormone
and hypophysectomy, *345
and hemochromatosis, 766-770
and intraocular pressure, *635
and new blood vessels formation, 816-823
and pituitary ablation, 824-832
in Pima Indians, *352-353
and pituitary ablation, *506
and resection of submaxillary and sublingual glands, *357
and skin capillary resistance measures, 297-300

REYE'S SYNDROME, *564

D-RIBOSE
and plasma insulin, *562

RNA
and kidney ribosomal protein synthesis, 649-654
-labeling in fibroblast cultures
and normal and diabetic insulin, 10-13
metabolism
and diet, 738, 744
and protein synthesis
and diabetes, 27-32
and insulin deficiency, *373
synthesis
and adenosine 3',5'-monophosphate, *841
and insulin and diabetes, *335
synthesis inhibitors
and biotin, 632
RO 6-4563
and diabetes treatment, *348

S

S 1702
and diabetes
and vascular disease, *353

SAIMIRI
and insulin immunoassays, *315

SALIVARY GLANDS
tryptic inhibitor
and diabetes, *357

SAND RATS
and hypothalamic lesions
and high-fat diet, *505

SCLERODERMA
and glucose intolerance
and hyperinsulinemia, *354

SECRETIN
and glucagon, *339
and glucose tolerance, *322
and insulin secretion, *507, 802
and diabetes, *445

SEROTONIN
and insulin secretion, 751

SERUM
alkaline phosphatase
and diabetic pregnancy, *367
anti-insulin
and gluconeogenesis and glycogenesis, *312
and insulin activity, *346
in insulin immunoassays, 34
and mammary gland metabolites, *636
and protein synthesis by liver ribosomes, 27-32
calcium and magnesium
and glucagon in juvenile diabetics, *365-366

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

cholesterol
and coronary artery disease, *506
and diet, *249
and low-sugar diets, *443
and oral contraceptives, *317
and sulfonylureas, *356
cholesterol, phospholipid and triglyceride
and hyperlipoproteinemia, *310
cortisol
and aged subjects, *842
free fatty acids
and diabetes control, 241-242
and growth hormone, *184
free fatty acids and glucose
and alloxan diabetes, *778
fucose
response to glucose, *376
gamma globulin and albumin
and alloxan diabetes, 164, 165
glucose
and sorbitol, *377-378
glucose and immunoreactive insulin
circadian variations in, *778
glucose, insulin, and growth hormone
and carbohydrate-free, isocaloric diet, *343
growth hormone
and Bovril and insulin, *562
and glucagon and vasopressin response, *565
and juvenile diabetes, 239-245
response to hypoglycemia, and adolescence, *185
growth hormones and free fatty acids
and starvation, *843
growth hormone, insulin, and sulfation factor
and leucine incorporation, *446
immunoreactive insulin
and chlorpropamide-induced hypoglycemia, *365
and glucose tolerance tests, 404-408, 410-415
in neonatal and adult mice, 137-138
and sodium acetoacetate infusion, *321-322
insulin
during glucose tolerance tests in women, 428-433
and hyperlipoproteinemia and atherosclerosis, *122
of hypoglycemic neonates, *314
in identical twins of diabetics, *509
and insulin immunoassays, *313
and insulin-treated diabetes, *368
and jejunoileostomy, *124
and nialamide, *185
in obese diabetics and nondiabetics, 217-218
and premature infants, *358
response to glucagon, and kidney failure, *252
and sulfonylureas, *356
and weight change and sulfonylureas treatment, *366
insulin, glucose and lipids
and vascular disease, *777
insulin and growth hormone
in prediabetic males, *371
lipids
and sucrose, *250
and sucrose and fat, *249
lipids, glucose and insulin
in starved rats with odd-carbon fatty acids diet, 201-204
lipids and lipoproteins
and diabetes, *362
lipoproteins
and diabetes complications, *378
C-peptide immunoreactivity
and beta cell activity, *332-333
potassium
and diabetic ketoacidosis, 496
protein changes
and blood flow in diabetics, *330
tri-, di-, and monoglycerides
and lipoproteins, *126
triglyceride
and hyperosmolar coma, *253

SEX
and cholesterol levels, 103
and diabetes
and Friedreich's ataxia, *124
in *Mystromys albicaudatus*, *123
and diabetes detection drive findings, 111
and diabetic ketoacidosis mortality, 490-491
and glucose disappearance rates in rats, *637
and glucose tolerance, 136
and insulin release
in normals and prediabetics, *378-379
and insulin secretion study, 65
and reactive hypoglycemia, 428-433
and serum immunoreactive insulin levels
and prednisone, 411-413
and serum protein, *330

SEX ORGANS
and diabetes, 557-559

SEXUAL DYSFUNCTION
in diabetic females, 557-559

SHEEP
and pancreas autotransplantation studies, *560
plasma insulin levels
and diet, *446

SHOCK
and antibodies to insulin, *506
and ketoacidosis mortality, *347

SICKLE CELL DISEASE
and diabetic ketoacidosis, 771-773

SKIN
capillaries
and S 1702 therapy, *353
fibroblasts
and C-14-O_2 production and insulin, *383
tests
and allergy to insulin, *563

SLEEP
and growth hormone release, *565
and juvenile diabetes, 691-694
and progeria, *564

SMOKING
and hypertension, *506

SOCIOECONOMIC STATUS
and length of partial remission period, *361

SODIUM ACETOACETATE
and insulin release, *321-322

SOMATOTROPHIN
action in fatty liver
in pancreatectomized-sympathectomized dogs, 673-676

SORBITOL
and metabolism, *377-378
and polyol pathway activity in aorta, *329

SOUTH AFRICAN HAMSTERS. *See Mystromys albicaudatus*

SPLEEN
and intravascular sickling, 772
lipids
and Wolman's Disease, *187

STARVATION. *See also* Fasting
and adenosine 3',5'-monophosphate response to glucagon, 130

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

and adipose tissue response to insulin, 46-50
and adrenergic receptor stimulation, *843
and anorexia nervosa, *360-361
and glucose availability
and heart function, *709
and growth hormone administration, *184
and insulin release
and sodium acetoacetate infusion, *321-322
and ketoacidosis
and urinary calcium excretion, *59-60
and obesity
in diabetics and nondiabetics, 214-225
and odd-carbon fatty acids, 200-204
and pregnancy, *507
and renal gluconeogenesis, 585

STEROIDS
and hyperosmolar nonketotic coma, 228
and plasma growth hormone response, *338

STREPTOZOTOCIN
and hypothalamic lesions
and obesity, *384
and insulinomas, *509
and insulin secretion by islets of Langerhans, 513-517

STREPTOZOTOCIN DIABETES
and biguanides, *711
and hepatic enzymes, 71-77
and homeostatic control of liver lipids, *354
and kidney, *712
and neuropathy, *331
in pregnant and nonpregnant rats, *562
and ventromedial hypothalamic nuclei destruction, *357-358

STRESS
and adrenergic control of basal insulin, *322
and diazoxide therapy
and hyperosmolar nonketotic coma, *635
and insulin dosage, 794-795

SUCCINATE
and kidney gluconeogenesis, *337

SUCROSE
and dietary fat, *249
and hyperlipoproteinemia, *310
and hyperlipemia, 833
and hyperlipoproteinemia, *250, *310
insulin response to
and obesity, *377
metabolism
and age and strain in rats, 518, 551

SUGAR
and blowfly larval development, *841
consumption
and diabetes prevalence, 103, 105-106
disappearance rates
and head injury, *364
transport, *711

SULFATE
uptake in rat aorta
and pancreatectomy and hypophysectomy, *59

S-35-SULFATE
uptake into aortic mucopolysaccharides
and insulin, *312

SULFHYDRYL-BINDING REAGENTS
and insulin release, *382

SULFONYLUREAS
glybenclamide, 745-754
and hypoglycemia, *356
and insulin release, *378
and liver metabolism, *564
and pregnant diabetics
and neonatal hypoglycemia, *314
RO 6-4563, *348
use of, *370
and weight change, *366

SURGERY
and diabetes management, *125
gastrectomy
and hypoglycemia, *58-59
hypophysectomy
and adipose tissue response to insulin during starvation, 46-50
and retinopathy, *345
and insulinomas, *189
and islet cell adenoma in infants, *843-844
jejunoileostomy, *124
and ketoacidosis, 494
pancreatectomy and hypophysectomy
and aortic sulfate uptake, *59
and sulfate uptake in rat aortas, *59
pancreatectomy in man, *188
pancreatectomy and sympathectomy
and fatty liver somatotrophin action, 673-676
pituitary ablation, *506
and diabetic retinopathy, 824-832
portacaval shunt
and insulin secretion and metabolism, *841
submaxillary and sublingual glands resection, *357

SYNALBUMIN INSULIN ANTAGONIST, *707
and diabetes, *184

T

TEMPERATURE
and α-methyl-glucose uptake by kidney cortex, *711
and carbohydrate metabolism, *708
and immunoreactive insulin release, *776-777

TESTICLES
of diabetic rats
and fatty acid metabolism, *123

TESTOSTERONE
and pancreas insulin, *124

TETRAGASTRIN
and glucagon secretion, *122
and plasma insulin response, *710

THAILAND
encephalopathy and fatty degeneration of viscera in, *564

THEOPHYLLINE
and adipose tissue metabolism, *380
and insulin secretion, 457-465
from fetal rat pancreas, 592-596

THIOL COMPOUNDS
and sulfhydryl-binding reagents
and islet tissue permeability, *318

THORACIC DUCT
lymph
and insulin secretion, *251

THROMBOSIS
and hyperosmolar coma, 308

THYMUS GLANDS
and acromegaly, diabetes and Cushing's Syndrome, *125

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

THYROID
function
and glucagon, *311
and glybenclamide, 751
and liver glucose utilization, *254

THYROTROPIN
and growth hormone, *124

THYROXINE
and ethanol-induced hypoglycemia, *254

TISSUES. *See also* Adipose tissue
buccal mucosa
glycogen content, *445
glucose assimilation studies, 519-521
glucosyltransferase activity
and diabetes, 645
isolated fat cells
and insulin and proinsulin studies, *187-188
mammalian
and lipogenesis, *317
mammary
in alloxan diabetic rats, *636
membrane structure studies, *444
pancreatic
in infants with hypoglycemia, *122-123
rat diaphragm
and insulin sensitivity, *318
resistance to insulin
and obesity, *336

TOLAZAMIDE
and insulin uptake by liver, *564

TOLBUTAMIDE
administration
and portal and peripheral vein immunoreactive insulin, 168-170
and beta-cell insulin study, *443
and hypoglycemia, *356
and immunoreactive insulin in portal and peripheral venous blood, 686-690
insulin response to
and maturity-onset diabetes, *252-253
and insulin secretion, *378, 449-455
and insulin uptake by liver, *564
and juvenile diabetes, *358
-like insulin secretion
conditioned in rats, *383-384
and liver glucose metabolism, *337
and pancreas islet metabolism, *364-365, 598-605
response
in monkeys, 153
tests
and diphenylhydantoin, 180
oral and intravenous, *505
and weight loss, 86-90
treatment
and UGDP study findings, *368

TRAUMA. *See also* Stress
head injury
and carbohydrate metabolism, *364

TRIAMCINOLONE ACETONIDE
and hexose uptake, *507

TRIGLYCERIDES
and insulin
and obesity, 664-671
synthesis
and gluconeogenesis, 224-225
and insulin, *347

TRI-HYDROXYMETHYL-AMINOMETHANE
and insulin secretion, *561

TRIIODOTHYRONINE
and lipolysis, cyclic AMP-C^{14} and oxygen consumption in isolated fat cells, *183
and obesity
and growth hormone, *315

TRYPSIN
and insulin, *184

TRYPTIC INHIBITOR
and salivary glands of normals and diabetics, *357

L-TRYPTOPHAN
and liver adenosine 3',5'-monophosphate, 130-131
and protein synthesis, 132

TUMORS
growth hormone-secreting
and pancreatic beta cell changes, 15-25
hepatoma
and insulin secretion, 607-613
and hypoglycemia, *122
insulinomas, *189
and proinsulin, *842
and streptozotocin therapy, *509
islet cell
and insulin secretion, *334
in newborn infant, *186, *843-844
and proinsulin secretion, *334-335
and psychiatric symptoms, *313

TURNER'S SYNDROME
and diabetes and gonadal dysgenesis, *189

TWINS
identical
and glucose tolerance and serum insulin, *509

U

UGDP STUDY
critique of results, *368

UNIT-MEMBRANE HYPOTHESIS, *444

UREMIA
and diazoxide therapy
and coma, 501-503
and glucose metabolism, *562
and insulin response, *565

URINE
5-aminolevulinate and porphobilinogen, *708-709
calcium
and ketoacidosis of starvation, *59-60
catecholamines
and adrenergic receptor stimulation, *843
epinephrine
and sporadic hypoglycemia, *636
glucose and acetone bodies
in juvenile diabetics, *182
glucose test, 289-295
17-hydroxycorticoids, catecholamines and 5-hydroxyindole acetic acid
and methysergide maleate, *321
insulin excretion
in children and adults, *123
polypeptide
and lipoatrophic diabetes, *315
sodium
and chlorpropamide, *60
tests
and chlorpropamide, *58

URTICARIA
and antibodies to insulin, *306
and fluorescein retinal angiography, *311

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

V

VAGUS NERVE
stimulation
and insulin and glucagon secretion, 78-81

VASCULAR DISEASE
and diabetes, *316
and carbohydrate utilization, *370
and nutrition, *350
and juvenile diabetes, *563
and serum insulin, glucose and lipids, *777

VASCULAR SYSTEM
blood flow
and glucagon, *560
changes
in diabetic children, *313
and cystic fibrosis, *183
fructose and glucose dispersion from, 193
and intracranial pressure, *843
and S 1702 therapy, *353
thrombosis
and hyperosmolar coma, 308
and tolbutamide, *383

VASOPRESSIN
and chlorpropamide, *58, *60
serum growth hormone response to, *565

VEINS
portacaval
and insulin secretion and metabolism, *841
and immunoreactive insulin and tolbutamide, 168-170, 686-690
renal
unilateral thrombosis, 308

VINCRISTINE
and insulin release, 257, 259-260, 262

VISION
and diabetic retinopathy, 821, 822
and hemochromatosis, 767
and meal stimuli
and plasma insulin, free fatty acids and glucose, *371

VOMITING
and pneumomediastinum, *357

W

WATER
deprivation
and diabetic hyperosmolar syndrome in rats, 94-97

WEIGHT. *See also* Body weight; Obesity
and blood sugar, 405, 406
change
and sulfonylureas, *366
and fasting hyperglycemia in adult-onset diabetics, 45
gain
and anorexia nervosa, *360-361
and insulin effectiveness in pregnancy, *363
and leucocyte zinc in diabetics, 210
loss, *563
and adipose tissue destruction, *563
and growth hormone, *315
and metabolism, 83-90
and odd-carbon fatty acids in rats, 200-203
obese and muscular
and metabolism, *842

WOLMAN'S DISEASE
and lipid studies, *187

X

XANTHOMAS
cutaneous
and hyperlipoproteinemia classifications, *316

Y

YTTRIUM-90
and pituitary ablation, 824-832

Z

ZINC
metabolism
and diabetes, 206-212

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

AUTHOR INDEX 1971

In this index are the names of authors of articles that have appeared in DIABETES and those whose articles have been abstracted in the Journal during 1971. Entries marked with an asterisk (*) indicate authors of material that appeared in the ABSTRACTS only. The Subject Index appears on page 1.

A

Abraham, R. R., 522-534, 535-541
Abrams, M. E., *635
Ackerman, Eugene, *343-344
Adams, Donald A., *345
Adams, Fae M., *311
Aiello, Lloyd M., *635
Åkerblom, Hans K., 15-26, *182
Albrink, Margaret J., *352, *359-360
Alcalay, D., *314
Alexander, James A., *560
Alexander, Kenneth R., *383-384
Aleyassine, H., *182, *840
Alford, F. P., 246-249, *707
Alfrey, Allen, *317-318
Allen, Constance M., *374
Allen, Donald O., *183
Almaraz-Ugalde, Arturo, 800-802
Alpers, D. H., *344
Altszuler, N., *124
Alvarez, Enrique, *331-332, *709
Alvarez, L. C., *707
Ammon, H. P. T., *345-346
Andersen, Dana K., *337
Andersen, Ole Ortved, 424-427
Anderson, D. M., *58
Anderson, Gail V., *367-368
Anderson, James W., *346
Andrews, Richard L., *185-186
Angel, A., *309
Antar, M. A., *249, *250, *309-310
Antoniades, Harry N., *346, *707
Appelt, Mary M., *711
Appert, Hubert, *251
Arieff, Allen I., *776
Arieh, Judith Ben, 308-309
Arky, Ronald A., 146-150, *363
Aronow, L., *507
Ashkar, E., 673-676
Ashmore, James, *309, *315, *323-324
Assaykeen, Tatiana A., *309, *316
Atwell, Marshall E., 193-199
Auerbach, E., *561
Avruch, Joseph, *335
Avruskin, T. W., *346-347
Ayala, Sixta, *123
Azarnoff, Daniel L., *844

B

Bacon, George E., *560
Bagdade, John D., 664-672
Bagul, C. D., *347
Baile, Clifton A., *707, *840
Baird, L., 513-518
Baird, Neil, *332
Bajaj, J. S., *309, *707
Baker, Lester, *635
Balagura-Baruch Sulamita, *124-125
Baldwin, R. L., *636
Balint, John A., *187
Ballard, F. J., *508
Ballintine, Elmer J., *352-353
Balodimos, Marios C., *125, *183, *311, 622-625, *635
Balsam, Marion J., *635
Barbor, P. R. H., *186
Bard, Harry, *778
Barnard, D. L., *59-60
Barnes, C. G., *318
Barry, Wayne S., *310-311
Baruch, Gellei, 308-309
Basabe, J. C., 449-456, 457-466, *711
Bass, Allan D., *183
Bassett, J. M., *776
Bates, Robert W., *776
Batt, R. A. L., *184
Battaglia, Frederick C., *312
Bauer, G. Eric, *332, *338-339
Baum, David, *776-777
Bauman, E. O., *355
Bautista, Arturo, *313
Bavli, Samuel, 92-98
Beatty, Clarissa H., *840
Beaven, D. W., *560
Beck, K., *188
Beck, John C., *315-316
Beck, Paul, *182, 271-275, *312
Becker, Dorothy J., 542-551
Becker, Kenneth L., *562
Beigelman, Paul M., *347, 490-500
Bell, J. P., *560
Bell, W. E., *249
Beloff-Chain, Anne, 522-534
Bencosme, Sergio A., 15-26
Bendixen, Gunnar, 424-427
Ben-Dyke, R., *707
Benevenga, N. J., *186
Bennett, Peter H., *348, *352-353, *374-375, *375-376, 756-765
Berchtold, Peter, 65-70, *348, *505
Beregi, L., *353
Beringer, A., *309
Bernardis, Lee L., *250, *357-358, 655-663
Berndt, W. O., *58
Bernstein, R., *344
Bersohn, I., *252
Bertrand, C. M., *312
Bhatia, S. K., *338
Bierman, Edwin L., 664-672
Bilder, Joan H., 615-621
Birchwood, B. L., *250, *309
Birnbaumer, Lutz, *341
Björntorp, Per, 65-70, *183, *348
Blach, R. K., *506
Blackard, William G., 168-170, 286-288
Blanche, Robert J., *560
Blanks, M. C., *356
Blazquez, E., *310, *560
Blecher, Melvin, *310
Bleicher, Sheldon J., *373-374
Blickens, D. A., *840
Blizzard, Robert M., *186
Block, Marshall B., *310, *332-333
Bloom, M. E., *310
Blum, Jurg W., *382-383
Boda, J. M., *312
Boden, Guenther, *321-322, *377-378
Bodey, Gerald P., *253
Boeck, Rose Mary, *840
Bongiovanni, Alfred M., *124, *637
Boniuk, Isaac, *443
Borg, Jo, *332
Boshell, B. R., *340-341, *347, *367
Bottger, Ingolf, *339
Boucher, Barbara J., *446

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

Bourgeois, Curtis H., Jr., *564
Bouzas, Andreas G., *635
Bowers, Mary, *368
Boyd, A. E., III, *561-562
Bradley, Edwin M., *711
Bradley, Robert F., 622-625
Brancato, Paul, *381-382
Brånemark, P.-I., *505
Brant, Bolek, *635
Brantley, James W., *189
Brauman, H., 467-475
Braun, T., *318
Braunsteiner, H., *563-564
Bray, George A., *310-311, *315, *348-349, *384, *445
Brech, W. J., *58, *508
Breine, U., *505
Brendel, K., 721-728
Brenner, Rodolfo R., *123, *189
Bressler, R., 721-728
Breuer, Joseph, 476-484
Brinegar, Charles H., *635
Brisson, G. R., *328-329
Brockman, W., *561
Brodoff, B. N., *505
Brody, H., *373
Broeckaert, Ivo, *561
Brown, G. A., *565
Brown, Henry, *840-841
Bruck, Bonnie A., *345
Brunt, Michael, *349
Brunzell, J. D., *342-343
Brush, James S., 140-145, *342
Büber, V., *505
Buchanan, Keith D., 78-82
Buchenau, H., *253
Buckley, G. C., *249, *250, *309-310
Buckley, Joseph P., *561
Buist, Neil R. M., *635
Burch, Thomas A., *374-375, 756-765
Burghen, George A., *342
Burke, Gerald, *311
Burkhardt, H., *317
Burns, Thomas W., *349, *362-363
Burr, Ian M., *592-597
Burrill, K., *323, *344, *373
Burrows, Belton A., *372-373
Burton, Robert A., *58
Burton, Stanley D., *369
Buschbom, Ray L., *369-370
Bushforth, Norman B., *374-375
Bussolati, G., *707-708
Butow, Ronald A., *777
Butterfield, W. J. H., *635
Byers, Sanford O., *443

C

Cahill, George F., Jr., *325, 785-799
Cain, Roy E., *841
Calder, J. S., 628-632
Calvayrac, Regis, *777
Camerini-Davalos, R. A., *361, *370-371
Campbell, James, *124
Campbell, John R., *635
Capella, C., *707-708
Caren, Raymond, *183
Carey, Larry, *341-342
Carlson, Richard H., *841
Carlson, Victor, *357
Carnelutti, Margherita, *183
Carrington, Elsie R., *311
Carroll, Hugh J., *776
Carter, D., *505-506
Carter, Guy A., *356-357
Carter, James R., Jr., *335-336
Cassar, J., *509
Cassuto, Y., *708
Caster, W. O., *709
Castillo, L., *712
Castro, Albert, *635
Celener, Mauricio Jadzinsky, *331-332
Cerasi, E., *183, *777
Cerchio, Gerard M., *349-350, *376
Cerletty, J., 83-91
Chacko, Claramma M., *635-636
Chalkley, Sylvia R., *777
Challoner, David R., *183, 276-281
Chambers, John W., *183
Chance, G. W., *565
Chang, Albert Y., 71-77, *356
Cha Pak, Yong, *311
Charles, M. Arthur, 501-503
Charles, Rene N., *350
Chayoth, R., *708
Chazan, Bernard I., *125, *183, *311
Cheitlin, M. D., *563
Chen, Ping Tuan, *250
Cheng, H., 816-823, 824-833
Cheng, J. S., *311
Cheng, Kwok-Kew, *184
Cherrington, Alan, *841
Chick, William L., 134-139, *327, 677-685, *841
Ching, K. N., *323, *344
Chisholm, D. J., *322
Chiumello, Giuseppe, *183
Chlouverakis, C., *184
Chochinov, R. H., *330-331
Chokroverty, S., *330
Chong, L., *350-351
Chowdhury, Faizur, *373-374
Chremos, A. N., *351, *353
Christensen, Niels Juel, *188, 297-301, *509
Christian, Joe C., *635-636
Christiansen, Robert O., *507
Cibeira, J. B., *709
Clark, Charles M., *351
Clarke, A. Murray, *843-844
Clayton, Barbara E., *562
Clayton, Patricia L., *309
Clodi, P. H., *712
Coddling, J. A., *843
Coello-Ramirez, Pedro, *315
Cohen, A. M., *561
Cohen, Burton D., *125
Cohen, Margo P., *59, *312
Cohen, R. D., *446
Cole, Harold S., 615-621
Colinas, R., *709
Collier, Boy N., Jr., 51-57
Collins, J. M., *708
Colwell, John A., *251, *607-614
Colwill, James R., *312
Conn, Harold O., *443, *708
Conn, Jerome W., *334-335, *354-355, *363, *711
Connelly, J. F., *843-844
Connon, J. Joseph, *378-379
Conway, M., *351-352
Coombs, R. R. A., *505-506
Cooperstein, S. J., *318, *844
Coore, H. G., *121-122
Corbo, Lucille, *183
Cordova, L. J., *561
Cornblath, Marvin, 156-161
Corredor, D. G., 428-434
Corvilain, J., 467-475
Cotmore, John M., *841
Cotton, Robert B., *564
Counts, Richard B., *315
Cowan, John S., *636
Crabtree, Ross E., *352
Craig, M. C., *708
Craighead, John E., *561
Cramer, J., *312
Cramer, M., 476-484
Crass, M. F., III, *778
Cravey, Eugene C., *250
Cremer, Guillermo M., *343-344
Crofford, Oscar B., *315
Csima, A., *249, *250, *309-310
Cuatrecasas, P., *336
Cunin, D., *188
Curry, Charles L., *560
Curry, Donald L., *249, *443
Curry, Katherine P., *249
Curtin, Richard, *341-342

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

Czech, Michael P., *184
Czyzyk, A., *708-709

D

Dade, Erica F., *184, 535-541
D'Alonzo, C. Anthony, *316-317
Danforth, Elliott, Jr., *343, 501-503
Dannenburg, W. N., *351
Danowski, T. S., 428-434
Dardennes, Guy, *185-186
Dashe, Alfred M., *345
Daughaday, William H., *329, *443
Davidoff, Frank, *325
Davidson, J. K., *843
Davidson, Mayer B., *184, *336
Davidson, Paul, *352, *359-360
Davies, E. W. G., 766-770
Davis, James R., *312
Davis, P. J., *561
Debons, Albert F., *249-250
DeBusk, Frank L., *564
DeCherney, Alan H., *367
DeJounge, Kristina, *183
del Castillo, E. J., 673-676
Delcroix, C., *467-475
del Guercio, M. José, *183
Demian, Y. K., *254
Dent, M. Marie, *709
De Palma, Ralph G., *359
Depperman, D., *126
Desai, K., *309
Deschamps, I., *188
Despopoulos, Agamemnon, *777
Dethier, V. G., *841
Devey, Madeleine, *505-506
Dietschy, John M., *59
Di Girolamo, Mario, *709
Diller, Erold R., *366
Disalvo, Joseph, *124-125
Distefano, G., *358
Dodd, Anita, *506-507
Dokas, Linda A., *841
Dolger, Henry, *375
Dolkart, Ralph E., 162-167
Dollery, C. T., 519-521, *842-843
Don, Ruth, *316
Donesa, A., *361
Dorf, Arthur, *352-353
Downing, Sylvia J., *842
Drash, Allan L., *186, *251-252, *317, *841
Drenick, Ernest J., *184, *707
Driscoll, S. G., *185
Duckworth, William C., *353
Duhalt, J., *353
Dunn, J. P., *506
Dupre, John, *315-316, *322
DuVall, Margaret, *446
Duwoos, H., *312
Dymock, I. W., 766-770

E

Eale, D., *189
Eaton, R. P., *329-330, *351-352
Eberlein, Walter R., *124, *637
Echemendia, Elsa, *252-253
Eckerling, Benjamin, *507
Edelman, Shmuel, 308-309
Edgar, Paul J., *843
Efendic, S., *777
Egeberg, Jorn, 424-427
Ehlers, W., *508
Ehrenreich, T., *370-371
Eisenstein, Albert B., *353-354, 577-585
El Defrawy, Souheir, *561
Elkeles, R. S., *506, *777
Elkington, Stephen G., *708
Eller, R. Roy, *709
Ellerman, J. E., *327-328
Elliot, Jennifer, 535-541
Elliott, Howard C., *378
Elrick, Harold, *184
Elsley, F. W. H., *58
Elsom, K. O., *506
Emerson, Kendall, Jr., 696-706
Englhardt, A., *506, *709
Ensinck, John W., *187-188
Epel, Rosa, 615-621
Epple, August, *354
Erwald, Rolf, 686-690
Esmann, V., *184-185
Espiner, E. A., *560
Espinosa de los Monteros Mena, Antonio, *185, *251
Etteldorf, James N., *342
Etzwiler, Donnell D., 51-57
Evans, David A. Price, 206-213
Evans, J. W., *312
Exton, J. H., *561

F

Fábry, P., *318
Faerman, Isaac, *331-332, *709
Fagerberg, S. E., *348, *505
Fain, John N., *184, *506-507
Fajans, Stefan S., *334-335, *354-355, *363, *842
Faloona, Gerald R., *339
Faludi, Georgina, *354
Fariss, Bruce L., 177-181
Farquhar, J. W., 416-423
Fasel, J. J., *185
Faulhaber, J. D., *445, *712
Feigin, Ralph D., *59
Felber, J. P., *185, *505
Feldman, Jerome M., *321, *337, *561-562, 745-755
Felig, P., *507
Feng, Louise Y., *122
Ferrou, Carlos A., 83-91, *842
Fertel, R., *598-606
Field, James B., *310, *323, *341-342
Filippone, Nicholas, *187
Fineberg, S. Edwin, *333-334
Fisher, D. J., *318
Flair, R. C., *563
Fleck, Henry, *125
Fleischmajer, Raul, *354
Flewelling, Judith H., 677-685
Floyd, John C., Jr., *334, *354-355, *363
Foa, Piero P., 586-591
Foglia, Virgilio G., *59, *312
Forsham, Peter H., 171-176, *344, *350-351
Foucar, Elliott, *323
Fox, Dora, *331-332, *709
Franckson, J. R. M., 467-475
Fraser, T. Russell, 214-227, *777, 816-823, 824-833
Frasier, S. Douglas, *185
Frawley, Thomas F., *374
Fred, Herbert L., *357
Frederickson, Donald S., *371
Freeman, Roger K., *355
Freinkel, Norbert, *338
Freund, H., *561
Freychet, Pierre, *334
Friedenberg, Ralph, 397-404
Friedman, Bernice, *312, *507
Friedman, Meyer, *443
Friedman, Sandor A., 302-307
Frohman, Lawrence A., *250, 266-270, *357-358, 444, 655-663
From, Annette, *249-250
From, George L. A., *335
Fumimoto, W. Y., *507
Fussgänger, R. D., *507

G

Gabbay, Kenneth H., *331
Gagliardino, Juan José, *185, *312-313, *778
Gale, Diana, *778
Gallagher, Thomas F., *315
Galloway, John A., *352, *366

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

Gang, Nicholas F., *443
Ganong, William F., *309, *316
Garcia, G., *360
Garnett, E. S., *59-60
Garnett, Jacqueline, *59-60
Garrison, Mary M., *776
Gassel, W.-D., *636
Gaut, Z. N., *355
Geiger, J. W., *711
Gellin, Milton E., *313
Genuth, Saul M., *710
Georg, Ralph H., *183, *328
Gerich, John E., 228-238
Gerritsen, G. C., *356
Gershberg, Herbert, *356
Gertner, Melvin, *383
Gibbs, Julia, *186
Giere, F. A., *186
Gilhoe, David D., *185-186
Gingerich, Ronald L., *356-357, *564
Gipstein, Robert M., *345
Girard, Donald E., *357
Gleason, Ray E., *371, *378-379
Glennon, Joseph A., *58, *317, *348-349
Glick, Seymour M., *366
Glocer, Leticia, *331-332
Glueck, C. J., *507-508
Goberna, R., *507
Godfrey, Jeand, *446
Godlowski, Z., *357
Goetz, Frederick C., *562
Gold, Ernest M., *184
Gold, Hugo, *843-844
Goldberg, Paul D., *313-314
Golden, P., 513-518
Goldfein, Alan, *309, *316
Goldfine, Ira D., *341
Goldman, Jack A., *507, *712
Goldman, Jack K., *250, 655-663, *357-358
Goldner, Martin G., *637
Goldrich, Nancy, *841
Goldstein, David E., *186
Goldstein, Jack, *368
Golob, Erich K., *562
Goodman, A. David, *123, *381
Goodman, Charles, *562
Goodman, Edward H., Jr., *312, *507
Goodman, H. Maurice, *313
Goodman, Joel W., *446
Goodman, M. N., *325
Gorden, Phillip, *334, *348
Gordon, Edgar S., *58, *317
Gordon, Edwin E., 92-98, *337
Gotlin, Ronald, 10-14
Goto, Masahiro, *250
Grad, Bernard, *842
Gragoudas, Evangelos S., *635
Grande, Francisco, *121
Grant, Alison, *383, *711
Grant, D. B., *186, *562
Grasso, S., *358
Grattan, William, *187
Gray, Jean G., *507
Greenbert, Robert E., *507
Greene, Harry L., *121
Greene, M. L., *507-508
Greene, Warner C., *373, 649-654
Greenfield, Joseph C., Jr., *560
Gregersen, Gunnar, *189, *253
Gregor, A., *708-709
Greider, Marie H., 388-396
Gries, F. A., *126, *253, *506
Griffiths, J. D., 766-770
Grimmel, K., *317
Grimminger, H., *710
Grinberg, Raul, *313
Grodsky, Gerold M., 171-176, *323, *326, *344
Grossin, Fr., *188
Grossman, Richard A., *564
Guggenheim, K., *314
Guilmette, J. G., *369
Gulati, P. D., *713
Gupta, S. L., *636-637
Gustafson, Anders, *348, *362
Guthrie, Richard A., *358, *361, *508
Gutierrez-Topete, Guillermo, *315
Gutman, Raul A., *372-373, *712, *842

H

Hadden, D. R., *508
Hadjikhani, H., *185
Hagedorn, J., *505
Hagen, T. C., *358-359
Hahn, Theodore J., *842
Haist, R. E., *843
Haley, John V., *313
Hall, Knowlton W., *250
Halperin, M. L., *309, *444
Halpern, Bernard, 162-167
Hampers, Constantine L., *562
Han, Paul W., *444
Hane, Satoshi, 171-176
Hanley, Henry G., *709
Hansen, Aa. P., *188, 239-245
Hansen, John D. L., 542-551
Hanson, R. W., *508
Harano, Yutaka, *359
Harders, H., *122
Hardman, J. G., *561
Hare, John W., *338
Harikul, Supha, *564
Harley, J. M. G., *508
Harmsen, Aage, *189, *251
Harper, A. E., *186
Harper, Larry, *359-360
Hart, D. S., *560
Hartman, Charles R., *445
Hartmann, W., *712
Hassenstein, P., *508
Hastillo, A., 428-434
Hatt, P. Y., *252
Hattner, R. S., *126
Havivi, Eli, *562
Haymond, Morey W., *59
Hazard, J., *313
Hazzard, W. R., *342-343
Hecht, Arthur, *356
Hed, Ragnar, 686-690
Heimberg, Murray, *253-254
Heinze, Eberhard, *710
Heinzel, W. H., *710
Heisig, N., *122
Hellman, Bo, *186, *188
Hems, D. A., 535-541
Henderson, J., *843
Henderson, J. R., *313
Hendler, E. W., *444
Hendricks, S., 542-551
Hengstmann, J., *508
Henkind, P., 519-521
Henneman, Dorothy H., *842
Hermansen, L., *186-187
Hernandez, A., *360
Hernández, Rodolfo Eduardo, *185, *778
Herrera, M. G., 46-50, *380
Herzig, Norman, *317
Hetenyi, Geza, Jr., *636
Heuser, Gunner, *345
Hiatt, Nathan, *187
Hiekkala, Hilkka, *182
Hilburn, Jean M., *185
Hill, C. Stratton, Jr., *253
Hill, D. W., 766-770
Hillman, Richard E., *121
Hiroyuki Sando, Jo Borg, *334
Hirschhorn, Kurt, *383
Hockaday, Judith M., *778
Hoff, Diana L., 271-275
Holland, G. W., *560
Hollenberg, C. H., *253
Hollinden, C. S., *361-362
Hollowell, Joseph G., Jr., *250
Holsclaw, Douglas S., *183
Horton, Edward S., *360-361
Hoshi, Mitsuru, *377
Howard, Evelyn, *713
Howard, John, *251
Hsia, Yujen E., *121

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

Hug, George, *121, *636
Hulse, Mildred, *356
Hunter, D. J. S., *444
Hurd, James B., *369-370
Hurwitz, Aryeh, *844
Husson, C. M., *312
Huttenlocher, Peter R., *121

I

Ide, Takehiko, *710
Illiano, G., *336
Ingebretsen, W. R., Jr., *323-324
Ipp, Tania, *778
Ipsen, J., *506
Irie, Minoru, *562-563
Irmscher, K., *253
Iturriza, Fermin C., *312-313
Iverson, Johan, 1-9
Iwatsuka, H., *361, *370-371
Izzo, Joseph L., *333
Izzo, Mary Jane, *333

J

Jackson, Doreen, *562
Jackson, James A., *844
Jackson, R. A., 214-227
Jackson, R. L., *358, *361-362
Jadzinsky, M., *709
Jahnke, K., *506
Jakob, Andreas, *318
James, W. P. T. *121-122
Jangaard, Norman O., *637
Jefferson, L. S., *335
Jensen, V. A., *188
Jessop, J. D., *318
Joffe, B. I., *253
Johansen, K., *188, *189, 239-245
Johnson, Brian F., *122
Jomain-Baum, M., *508
Jonsson, Anders, *348, *362
Joplin, G. F., *506
Joslin, Allen P., *125
Juhl, Erik, *124
Jung, Y., 428-434
Jungas, Robert L., *444
Jurgensen, J. C., 771-773

K

Kaden, Melvin, *341
Kadish, Arnold, *362
Kaess, H., *508
Kaffarnik, H., *636
Kagan, Avir, *366, *505
Kahan, Miles, *313-314
Kajinuma, Hiroshi, *340
Kajtar, T. J., *508
Kalant, N., *311-312
Kalbfleisch, John M., 99-108, 289-296
Kalkhoff, Ronald, 83-91, *338, *842
Kallee, E., *710
Kallos, A., *250 *309-310
Kanazawa, Yasunoir, *60, *326, 592-597
Kaneto, Akio, *122, *187, *710
Kaplan, B. S., *778
Karacan, Ismet J., *564
Karam, John H., 171-176, *323, *344, *350-351
Karsznia, R., *636
Kasemir, H., *314
Katz, H. P., *563
Katz, Jack, *349
Katz, Joseph, 187
Kawamura, T., *843
Kaye, Robert, *635
Keenan, John P., 206-213
Keiser, G., *505
Kelley, Vincent C., *311
Kelly, Heather, 151-155
Kelly, J. J., *344
Kemball M. L., *314
Kemmler, Wolfgang, *332
Kennas, A. L., *708
Kenny, Frederic M., *251-252
Kerp, L., *314
Kettyle, William M., *58
Khurana, R. C., 428-434
Kikkawa, Ryuichi, *377
Kikuchi, Masatoshi, *710
Kilo, Charles, *329
Kim, H. J., 83-91
Kinney, J. M., *711
Kipnis, D. M., *329, *344
Kirsteins, L., *358-359
Kirtley, William R., *357
Kitabchi, Abbas E., *342, *353
Klachko, D. M., *362
Kleinsmith, Lewis J., *841
Kling, Arthur, 156-161
Klotz, A., *313
Knittle, Jerome L., *383
Knoller, Mechthilde, *560
Knopf, Ralph F., *354-355, *363
Knopp, Robert H., *363
Knowles, Harvey C., Jr., *363-364
Koehler, J. O., *335
Koffler, Herbert, *636
Kogut, Maurice D., *637
Kohner, E. M., 816-823, 824-833, *842-843
Kolodny, Robert C., 557-559
Koncz, Lajos, *311
Konjin, A. M., *314
Kopp, April, *777
Korczyn, A. D., *563
Kosaka, Kinori, *122, *187, *710
Kostos, Vincent, *507
Kotler-Brajtburg, J., *327-328, *364-365
Kral, Vojtech A., *842
Kraner, K. L., *123
Krebs, H. A., *187
Krees, S., *711
Kreines, Kenneth, 774-775
Kreisberg, Robert A., *122, *324, *378, 739-744
Krezdorn, W., *126
Krimsky, Isidore, *249-250
Kroeger, A., *122
Kronfeld, David S., *382-383, *710-711
Kryston, L. J., *364, *376
Krzanowski, J. J., Jr., *364-365, *598-606
Ksczurowski, Michael, *314
Kumar, Dinesh, *365
Kummerle, F., *188
Kuo, Peter T., *122
Kuruvilla, Th., *357
Kuzuya, Takeshi, *60, *710
Kyriakides, Emilios C., *187
Kyriakopoulos, Adrian, 734-738

L

Labram, Cl., *314
Lacy, Paul E., 257-265
Lain, R. F., 428-434
Lambert, Andre E., *326, 385-388, 592-597
Landgraf, R., *327-328
Langer, L., *505
Langley, Paul E., *349
LaNoue, Kathryn F., *444
Laor, J., *508
Larkin, Edward C., 282-285
Lars, Sullivan, *183
Larsson-Cohn, U. L., *187
Lauri, Hector C., *185
Lavine, Lawrence, *359
Lavine, Robert L., 134-139, *311, 677-685
Lavis, Victor R., *187-188
Lawrence, A. M., *358-359
Lazarow, Arnold, *318, *844
Lazarus, Norman R., *712, *842
Leboeuf, Gilles, *565

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

Lebon, F., *353
Lebovitz, Harold E., *337, *561-562, 745-755
Leclercq-Meyer, V., *188
Lecocq, Frank R., 282-285, *711
LeCompte, Philip M., *341
Lee, James B., *374
Lee, Sin Hang, *840
Lefebvre, P. J., 435-442
Legg, Merle A., *341, 622-625
Lehnert, H., *636
Leitner, J. W., *328
Lerner, R. L., *342-343
Lernmark, Ake, *188
Lestradet, H., *188, *314
Leveille, Gilbert A., *254, *844
Levin, Seymour R., 171-176
Levine, Robert A., *188
Levine, S., *326
Levitan, Ruven, *562
Levitsky, Lynne L., 156-161, *365
Lev-Ran, A., *508
Levy, Leonard J., *637
Levy, Robert I., *251, *371
Liberman, Henry, *842
Lieberman, Phillip, *563
Liebermeister, Hermann, *253, *506, *563
Lifshitz, Fima, *315
Like, Arthur A., *60, 134-139, *327, *841
Limbeck, George A., *311
Lin, B. J., *843
Lipman, Richard L., 282-285, *711
Lische, H.-J., *563-564
Little, J. A., *249, *250, *309-310
Little, J. Russell, *315
Little, John R., *250
Lockwood, Dean H., *336, *843
London, G., *313
Londono, Javier H., *315, *365-366, *445, 552-556, *844
Long, C. L., *711
Longnecker, D. S., *249
Lopez, N. L., 449-456, 457-466, *711
Lorch, E., *711
Loridan, Liliane, *125, *508-509
Louis, Lawrence H., *315, *711
Love, Tommy L., 282-285
Lowrey, George H., *560
Lowrie, Edmund G., *562
Lowy, C., 214-227, *777, *842-843
Lubchenco, Lula O., *778
Lubow, Martin, *711
Lucas, C., *249, *309
Lucena, Guillermo, *563
Lucke, Christoph, *366
Ludwiczak, H., *188
Luft, R., *183, *777
Lundbaek, Knud, *188, *189, *251
Lutcher, Charles L., 177-181
Luyckx, A. S., 435-442
Lynch, V., *507

M

Mabry, C. Charlton, *313
Macaulay, Michael B., *843
McDaniel, H. G., *367
McEvoy, Donald, *367
McGarity, William C., *189
McGuigan, James E., 389-396
McHale, Phillip A., *560
McIver, C., *314
McLaughlin, Carol L., *840
McLaurin, Robert L., *364
McMahon, F. Gilbert, 734-738
McMaster, D., *707
McMillan, Donald E., *330
McNamara, Pamela, *711
Madison, Leonard L., *324
Magos, C., *360
Maha, George E., 734-738
Mahan, Clare M., 811-815
Mahler, Richard J., *336-337, *379-380
Makdisi, Thomas W., 134-139
Makley, Torrence A., Jr., *711
Mako, Mary, *332-333, *380-381, *397-404
Makowski, Edgar L., *312
Makulu, David R., 33-45, *356, *446
Malaisse, Willy J., *188, 257-265, *445, *328-329, 513-518
Malaisse-Lagae, Francine, 257-265, *445, *328-329, 513-518
Maler, Mario, *331-332, *709
Malik, G. B., *713
Malins, J. M., *252
Manchester, K. L., *60
Mandel, Emanuel E., *313-314
Mann, George V., *315
Mardell, R. J., *59-60
Marios, C., *311
Markussen, J., *189
Marliss, Errol B., 592-597
Marshall, Alexander, *564
Martin, Donald B., *335-336
Martin, E., *313
Martin, F. I. R., 246-249, *707
Martin, Julio M., 15-26, 151-155
Martin, Malcolm M., 228-238
Martin, R. J., *636
Maruhama, Yoshiskue, *564
Massaglia, A., *315
Matschinsky, F. M., *327-328, *364-365, 598-606
Matsuda, Ayako, *366
Matz, Robert, *366
Mayer, Jean, *840
Mayhew, Dale A., *315
Mazar, Stephen, *313
Medard, Frantz, *350
Mehlman, Myron A., *445
Mehnert, H., *509
Mehtalia, Suresh D., *365
Meier, V., *505
Melani, F., *317
Mellati, Ali M., *315-316
Menahan, L. A. *252
Mendelson, Lazar, *316
Merimee, Thomas J., *333-334
Merrill, John P., *562
Mersmann, H. J., *712
Meschia, Giacomo, *312
Messina, A., *358
Mestman, Jorge H., *355, *367-368
Metz, Robert, *368, 397-404, *563
Metz, Th., *709
Metzger, Boyd E., *338
Metzger, R. P., *369
Meyer, E., *189
Meyer, Julia, *445
Mialhe, P., *188
Miles, David W., 1-9
Miller, Leona V., *365, *368
Miller, Max, *348, *352-353, *359, *374-375, *375-376, 756-765
Miller, Michael, *58
Miller, Myron, *60
Mills, L. C., *364, *376
Milner, R. D. G., *314
Milunsky, Aubrey, *445
Mintz, D. H., *310
Misbin, Robert I., *843
Misugi, Kazuaki, *122-123
Misugi, Nobuko, *122-123
Mitchell, Marvin L., *564-565
Mitsuru, Hoshi, *637
Mizuno, Yoshiatsu, *122
Mobley, P. W., *369
Modai, J., *313
Mohs, J. M., *362
Molines, M., *364, *376
Molnar, George D., *125, *343-344
Moloney, M., 214-227
Mondon, Carl E., *369
Montgomery, April, 10-14
Montgomery, D. A. D., *508
Montoya, E., *560
Moody, A. J., *189

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

Mooney, Joseph H., 109-116
Moore, Charles, *562
Moore, D., *338
Moore, Robert H., *369-370
Moorhouse, J. A., *330-331
Morgan, H. E., *335
Morrison, Anthony D., *329
Moschella, Samuel L., *316
Moses, Arnold M., *60
Mothon, Stella, *310-311
Mozzoli, M. A., *321-322
Mudd, S. Harvey, *778
Muhe, E., *316
Mühlendahl, K.-E Von, *384
Muogbo, D. N. C., *314
Murthy, V. K., *379
Myer-Bertenrath, J. G., *636
Myers, Virginia, *840-841

N

Nadler, Henry L., *635-636
Nafz, M. A., *342
Nahir, Menachem, 308-309
Najenson, Theodore, *316
Najjar, Samir S., *123
Nankin, Howard, *334
Natelson, Ethan A., *357
Needham, L. B., *356
Nehrlich, Sooja, *332
Nelson, L. R., *123
Nelson, Norman C., 168-170, 286-288
NepoKroeff, C. M., *708
Nerup, Jorn, 424-427
Neuberg, Hans W., *370
Newberne, Paul M., 151-155, *382
Nibbe, Albert F., 404-409
Nichols, George, Jr., *841
Nielsen, J., *184-185, *189
Niteck, Danute, *446
Noble, R. E., *351
Noe, Bryan D., *338-339
Nourok, David, *370
Nourse, C. H., *314
Novack, Leila, *506-507
Nygren, Arne, 686-690

O

O'Brien, Donough, 10-14
Oesterling, M. Jean, *311
Ohira, S., *843
Ohtani, M., *506
Ohtsuki, Iwao, *250-251
Oji, Nobuyoshi, *637
Olsen, T. S., *188
Olson, Lloyd C., *564
Onofrio, J., *361
Oppermann, W., *361, *370-371
Orci, Lelio, *326, 385-388
Orme, M. L'E., 519-521
Orskov, H., *188
Orvis, Harold H., *377-378
Orzeck, Eric A., 109-116
Osnes, J. B., *186-187
Ostendorff, Martha E., *250
Osterby, R., *188
O'Sullivan, John B., *363, 811-815
Otsuka, Kensaku, *316
Otsuka, Masanori, *250-251
Owen, John A., Jr., 109-116
Owen, O. E., *321-322
Owen, W. Crawford, *324, *378, 739-744
Oxley, M. J., 771-773
Ozawa, Hitoshi, *60, *316

P

Packer, J. T., *123
Pagliara, Anthony S., *123
Pairent, Frederick, *251
Pandian, M. R., *636-637
Panisset, A., 816-823, 824-833
Parameswar, K. S., *330
Park, Byung N., *371
Park, C. W., *561
Parker, Donal C., *565, 691-695
Parra-Covarrubias, Adalberto, *371, 800-802
Parrilla, R., *325
Patel, M. S., *508
Patel, Tehmi, *327
Patrick, D., 428-434
Patterson, Roy, *563
Pauk, G. L., 129-133
Paul, Betty, *187
Paul, T. N., *372
Pearson, Margaret J., 246-249, *707
Pek, Sumer, *334-335, *354-355, *363
Pell, Sidney, *316-317
Peluffo, Raul O., *123, *189
Penhos, Juan C., *712, *842
Pennington, L. F., *122
Penny, Robert, *564
Pepin, Juna, *251
Pereira, J. N., *637
Perkins, J. R., *187
Perlman, Janice, 162-167
Permutt, M. A., *344
Persson, B., *123
Peterson, Daniel T., *373, 649-654, 729-733
Peterson, G. Brunn, *184-185
Peterson, James, *332
Pfeiffer, E. F., *445, *712
Pfleger, B., *712
Phang, James M., *842
Phelps, P., *326
Pictet, R., *326
Pidduck, Heatl.er G., 206-213
Pilkington, T. R. E., 214-227
Pimstone, Bernard L., *189, 542-551
Pi-Sunyer, F. Xavier, 200-205, *372
Plackova, Anna, *445
Pocelinko, R., *355
Podolsky, Stephen, *123-124, *372-373
Poffenbarger, Philip L., *184, *251, 677-685
Polmar, Stephen H., *564
Popovich, Penny A., *349-350, *376
Porte, Daniel, Jr., *322, *340, *342-343, *383-384, 664-672, *776-777
Porter, J. W., *708
Porter, Robert D., *445
Posner, N. A., 476-484
Poulsen, Jacob E., 424-427
Pratt, William B., *507
Prchkov, V. K., *354-355
Prendergast, J. J., *373
Prigge, William F., *121
Prockop, Leon D., *843
Pruett, E. D. R., *186-187
Przbyski, Ronald J., *710
Pyke, D. A., *509

Q

Quaade, Flemming, *124
Quickel, K. E., *321
Quijada, C. Lopez, *310, *560

R

Rabkin, Ralph, *251
Raithel, D., *316
Raju, K. G., *509
Raju, T. R. S., *713
Rakow, Robert B., 302-307
Ramberg, C. F., Jr., *710-711
Rand, Robert W., *345
Rannels, D. E., *335
Rappaport, A. M., *843
Raptis, S., *445, *507, *712
Raskin, Niel H., *58
Rastogi, Krishna Sudha, *124
Rathgeb, I., *124
Rau, R. M., *712

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

Rea, Claire, *711
Reaven, Gerald M., 27-32, *373, 416-423, 649-654, 729-733
Recant, Lillian, *712, *842
Reddy, W. J., 129-133, *340-341, *347, *367
Reed, J. W., *373
Rees, Klaus O., *324
Rehfeld, Jens F., *124
Reichard, G. A., Jr., *321-322
Reitano, G., *358
Renold, Albert E., *326, 385-388
Reske-Nielsen, Edith, *189, *251
Reyes, M. G., *330
Reynertson, Richard, *381
Rialdi, G., *315
Ricketts, H., *372, *509
Rietti, C. T., 673-676
Riggi, S. J., *840
Rishi, Surendra, *562
Rivera, Irene, *371
Rivera-Rodriguez, Irene, 800-802
Rizza, R. A., *778
Robertson, R. P., *322
Robinson, B. H., *444
Robinson, C. A., Jr., *340-341
Robinson, M. J., *843-844
Robison, G. Alan, *349
Rodda, Bruce E., *366
Rodman, Harvey M., *373-374
Rodriguez, Ricardo R., *185
Roe, Thomas F., *637
Rojas, L., *360
Rojdmark, Sven, 686-690
Roldan, Alicia G., 673-676
Rommel, K., *317
Roncone, Angela, *333
Root, Allen W., *124, *637
Root, Howard F., *125
Rosa, U., *315
Rose, S. D., *123
Rosenberg, Arthur A., *712
Rosenberg, David M., *710
Rosenberg, Gilbert M., *842
Rosenbloom, Arlan L., *124, *365-366, *374, *564, *844
Rosenman, Ray H., *443
Rosenmann, E., 803-810
Rosenquist, Robert, *370, *379
Rosevear, John W., *343-344
Ross, Jeffrey, *712
Rossi, C. A., *315
Rossini, Aldo A., *374
Rossman, Lawrence G., *565, 691-695
Roth, Jesse, *341, *348
Roth, Nathan H., *345
Rothstein, Jeanne, *370
Rouiller, Charles, *326, 385-388
Roussy, Jacques, *565
Roxe, David M., *124-125
Roy, Claude C., 10-14
Rubenstein, Arthur H., *252, *310, *332-333, *380
Rubino, F. A., *330
Rubinstein, David, *315-316
Rudd, B. T., *565
Rufener, Claude, 385-388
Rushforth, Norman B., 756-765
Rutter, W. J., *326
Ryan, Jerome R., *125, 734-738
Ryan, Will G., 404-409

S

Sabata, V., *254
Sachs, Bernard A., *317
Sadeghi-Nejad, Abdollah, *125, *508-509
Saeed, S. M., 771-773
Safir, Aran, *375
Sailer, S., *563-564
Salamonsen, L. A., *560
Salmon, William D., Jr., *446
Saltzman, Herbert A., *564
Salzano, John V., *564
Samaan, Naguib A., *249, *253
Sandbank, Uri, *316
Sanderson, D. J., *505-506
Sandhofer, F., *563-564
Sando, H., *60
Santeusanio, Fausto, *339
Saunders, Harry L., *507
Savory, John, *844
Sawin, Clark T., *564-565
Schaeffer, L. D., *326-327
Schaich, Fries, *189
Scharf, Yehuda, 308-309
Schiff, D., *314
Schless, Guy Lacy, *375
Schlierf, G., *508
Schloeder, Francis X., *565
Schmid, F. G., *323
Schnatz, J. David, *250, *357-358, 655-663
Schneider, Diana I., 71-77, *356
Schneider, J., *636
Schnure, Joel J., 282-285, *711
Scholz, Roland, *318
Schonfeld, G., *712
Schreiber, William, *708
Schreibman, Paul H., 146-150
Schricker, K. Th., *316
Schröder, K. E., *445, *712
Schubert, William K., *121, *636
Schultz, Robert B., *371, *564
Schumer, B., *842
Schwartz, Maurice, *330
Schwartz, Richard H., *367
Schwartz, Theodore B., 404-409
Scrutton, Michael C., *446
Seegmiller, W. Y., *507-508
Segal, Stanton, *711
Selenkow, Herbert A., 696-706
Selibiansky, Hanna, *316
Senior, Boris, *125, *508-509
Senyk, George, *446
Shack, Michael J., *375-376
Shah, Jayendra H., *349-350, *376
Shajia, Khan, *335
Shames, D. M., *710-711
Shapcott, Dennis, 10-14
Shaw, R. A., *364, *376
Sheinkopf, J. A., *187
Shen, S. W., 416-423
Sheremata, William A., *123-124
Sherman, Barry M., *334-335, *354-355
Shipp, Joseph C., 552-556, *778
Shrago, Earl, *317
Shreeve, Walton W., *377, *637
Shroyer, Lois A., *342, *377
Shuman, Charles R., *321-322, *377-378
Shwachman, Harry, *183
Siegal, Alan M., *324, *378, 739-744
Silverman, S., *373
Silvers, A., 416-423
Silverstein, Murray N., *125
Silverstone, F. A., 476-484
Simmons, D. A., *250
Simms, Quita, *777
Simon, E., *508
Simon, James D., *346, *707
Simon, Norman M., *251
Singh, Hira, *251
Sirtori, Cesare, *844
Sisk, Charles W., *349
Sixta, A., *189
Sjöström, Lars, *183
Skinner, N. Sheldon, Jr., *709
Skriver, Christian P., *841
Slavinski, Robert H., *637
Slotnik, B., *505
Smelo, Leon S., *378
Smith, Blanca, *122-123
Smith, C. K., *509
Smith, Fred G., Jr., *185
Smith, Thomas J., *564
Sobel, J., *189
Sodoyez, Jean-Claude, 586-591
Sodoyez-Goffaux, Francois, 586-591

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

Soeldner, J. Stuart, *371, *378-379, *562, 677-685
Sokal, Joseph E., *317, *713
Solcia, E., *707-708
Solomon, H. M., *355
Solomon, Solomon S., *342
Sotos, Juan, *122-123
Souadjian, Jacques V., *125
Spencer, J. L., *711
Spergel, Gabriel, *637
Sperling, Mark A., *251-252, *317
Spiro, Mary Jane, 641-648
Spiro, Robert G. 641-648
Spitz, I. M., *252
Spitzer, John J., *250
Spratt, Irving L., *370, *379
Spring, Maxwell, *125
Srivastava, Laxmi, *364
Stauffacher, Werner, *326, 385-388
Steele, R., *124
Steenstrup, C., *189
Steinbaugh, Bobby J., *565
Steinberg, Arthur G., *374-375, 756-765
Steiner, Donald F., *332-333, *334
Steiner, George, *379
Steiner, Sheldon, *251
Steinhilber, S., *314
Steinke, Jurgen, *125, *251, *327, *345-346, *561, *710
Stephan, Leila, *123
Stephens, Jennifer M., 485-489
Sterky, G., *123
Stiltz, J. G., *361-362
Stoll, R. W., *252, *509
Storvick, W. O., *361-362
Strachan, I. M., 626-627
Strack, Inge, *353-354
Strandvik, B., *123
Strauss, Franklin G., *844
Stroeh, L., *361-362
Stubbe, P., *254, *713
Stuhlman, R. A., *123
Sukama, Maki, *562-563
Sullivan, Mary Ann, *844
Sulway, M. J., *252, 485-489
Sundblad, Lars, 686-690
Sundby, F., *189
Surmaczynska, Barbara, 397-404
Sussman, Karl E., 33-45, *317-318, *328
Sutherland, E. W., *561
Swynghedaw, B., *252
Szabo, Olga, *336, *379-380

T

Talwar, G. P., *636
Tamasi, G. G., *707
Tanner, J. M., *777
Tasaka, Yoshimasa, *122
Tashjian, Andrew J., *637
Tatarsky, Ilana, 308-309
Taylor, Floyd, *341-342
Taylor, K. W., *509
Taylor, Malcolm H., *713
Taylor, William F., *343-344
Tayot, J., *312
Teitelbaum, A., 803-810
Telib, M., *507
Tengström, B., *187
Terkildsen, A. B., *509
Terkildsen, Birgitte, 297-301
Terry, M., *711
Tetreault, Leon, *565
Thaler, H., *309
Theodoridis, C. G., *565
Therriault, D. G., *445
Thevaos, Theo. G., *250
Thiery, J. P., *313
Thomas, G. B., *355
Thompson, Robert G., *564
Thorburn, G. D., *776
Tiblin, Gosta, 65-70
Tichet, J., *188
Tiernan, J. R., *314
Tobin, R. B., *445
Todd, Janet, *509
Toews, C. J., *325
Torno, N., *346-347
Touber, J. L., *252
Toussaint, C., 467-475
Trachtenberg, John, *842
Tragl, Karl H., 27-32
Trenkle, Allen, *446
Trenner, R., *188
Trueheart, P. A., 46-50, *380
Tsai, A., *380-381
Tsushima, Toshio, *562-563
Tsutsumi, Victor, 15-26
Turinsky, Jiri, *381
Turkeltaub, P., 428-434
Tyler, Jean M., *340
Tzagournis, Manuel, *381

U

Ullyot, G. L. E., *330-331
Ulvedal, Frode, *711
Unger, Roger H., *252, *339, 834-838

V

Vaishnava, H., *713
Vallance-Owen, J., *309, *707
Valtin, Heinz, *58
Van, As. M., *252
Vance, James E., 78-82, *509
VanderLaan, E. F., *565
VanerLaan, W. P., *565
Van Leeuwen, G., *508
Van Lente, Fred, *777
Varandani, P. T., *342, *377
Varma, Kamlesh, 696-706
Varsano-Aharon, Nora, *252-253
Vassallo, G., *707-708
Velasco, C., *370-371
Veneziale, Carlo M., *324-325
Verdy, Maurice, *565
Vereerstraeten, P., 467-475
Vernon, R. G., *126
Vichick, Diana, 33-45
Viehweger, I., *253
Vigo, R., *358
Viktora, J. K., 449-456, 457-466, *711
Vince, F. P., *446
Vinik, A., *253
Vins, M., *508
Vogelberg, K. H., *126
Vogler, Nancy J., *329
Volk, Bruno W., *381-382, *713
von Mikulicz-Radecki, J.-G., *508
Vost, A., *253
Voyles, N., *712
Vrána, A., *318
Vranic, Mladen, *841

W

Wachman, A., *126
Wagle, S. R., *323-324
Wagner, F. C., *254
Wahl, P., *126
Waiches, H., *361
Waldman, Robert H. 552-556
Walker, D. G., *126
Walker, Jon, *359-360
Walker, M. M., 513-518
Walker, Mary O., 257-265
Walter, K., *508
Ward, J. D., *318
Warner, Nancy E., *347-348
Washington, Annabelle, *188
Wasser, A. H., *563
Waterhouse, Christine, 193-199
Waterhouse, J. P., *445
Watkins, Dudley, *318, *382, *844
Watkins, P. J., 485-489
Watson, B. M., 628-632
Weinhouse, Sidney, *312, *507
Wellmann, Klaus F., *381-382, *713

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

Weser, Elliot, *254
Wessels, M., *253
West, Kelly M., 99-108, 289-296
Westervelt, Frederic B., Jr., *565
Whedon, G. Donald, *334
White, Priscilla, *125, 696-706
White, R. J., *254
Whitecar, John P., Jr., *253
Whitehouse, F. W., 771-773
Whitty, C. W. M., *778
Wichelow, Margaret J., *635
Wick, Arne N., *369
Wide, L., *187
Wiechel, Karl-Ludvig, 686-690
Wigley, Frederick M., 552-556
Wilber, John F., 607-614
Wilcox, Henry G., *253-254
Wilder, M. W., *326-327
Wiley, Joyce H., *254, *844
Williams, Gail D., *382
Williams, Robert C., *251
Williams, Robert H., 78-82, *187-188, *252, *326-327, *509
Williams, Roger, 766-770
Williams, T. F., *561
Williamson, D. H., *778
Williamson, John R., *318, *444
Williamson, Joseph R., *329
Wilson, Dana E., 146-150
Wilson, Jean D., *59
Wilson, Robert B., 151-155, *382-383
Winegrad, Albert I., *329
Winkler, B., *124
Winnick, Sheldon, *254
Wohlueter, R. M., *186
Wolf, H., *254, *713
Wolf, Stephen A., *383
Wolff, Frederick W., *122, *383, 449-456, 457-466, *711
Wolff, Kirsch M., *317-318
Wolfman, Lila, *317
Wood, Scott H., 552-556
Woods, Stephen C., *383-384
Wright, A. D., 214-227
Wright, Peter H., 33-45, *315, *356-357, *446, *564
Wuthier, Roy E., *841
Wyllie, A. D. H., *777

Y

Yalow, Rosalyn S., *252-253
Yang, Mabel M. P., *184, *254
Yashon, D., *254
Yde, H., *189
Yeung, C. Y., *713
Ylikahri, Reino H., *254
York, David A., *384
Young, Eusebio C., *352, *366
Young, J. L., *777
Young, Sister John M., *254
Younger, Donna, 696-706

Z

Zahnd, G. R., *384
Zeigler, M., *843
Zilbervarg, J., *709
Zimmerman, Hyman J., *372-373
Zinn, William, *840
Zofel, P., *636
Zorrilla, E., *360

DIABETES: VOLUME 20 (1971) PAGE NUMBERS BY ISSUE

January, 1-64
February, 65-128
March, 129-192
April, 193-256
May, 257-320
Supplement 1, 321-384
June, 385-448
July, 449-512
August, 513-576
September, 577-640
October, 641-720
November, 721-784
December, 785-848

American Diabetes Association, Inc.
18 East 48th Street
New York, N. Y. 10017